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Abstract 
Emily Keller Blue 
 
DEATH-ASSOCIATED PROTEIN KINASE REGULATES VASCULAR SMOOTH 
MUSCLE CELL SIGNALING AND MIGRATION 
 
Cardiovascular disease is the number one cause of death for Americans. 
New treatments are needed for serious conditions like atherosclerosis, as it can 
lead to stroke and heart attack. Many types of cells contribute to the progression 
of cardiovascular disease, including smooth muscle cells that comprise the 
middle layers of arteries. Inappropriate growth and migration of smooth muscle 
cells into the lumen of arteries has been implicated in vascular diseases. Death 
associated protein kinase (DAPK) is a protein that has been found to regulate the 
survival and migration of cancer cells, but has not been well characterized in 
vascular cells. The objective of this work was to determine the signaling 
pathways that DAPK regulates in smooth muscle cells. 
These studies have focused on smooth muscle cells isolated from human 
coronary arteries (HCASM cells). We have determined that HCASM cells 
depleted of DAPK exhibit more rapid migration, showing that DAPK negatively 
regulates migration of vascular cells. Results from a focused RT-PCR array 
identified matrix metalloproteinase 9 (MMP9) as a gene that is increased in cells 
depleted of DAPK. MMP9 is an important enzyme that degrades collagen, a 
vii 
component of the extracellular matrix through which smooth muscle cells migrate 
during atherosclerosis. We found that DAPK regulates phosphorylation of the NF-
κB transcription factor p65 at serine 536, a modification previously found to 
correlate with increased nuclear levels and activity of p65. In DAPK-depleted 
HCASM cells, there was more phosphorylation of p65, which causes increased 
MMP9 promoter activity. Additional experiments were conducted using 
transgenic mice in which the DAPK gene has been deleted. By studying these 
mice, we have determined that under some circumstances DAPK augments 
maximal MMP9 levels in mouse carotid arteries which have been injured by 
ligation surgery via other signaling pathways. 
MMP9 has been previously implicated as a protein that promotes vascular 
diseases such as atherosclerosis. Our research in identifying DAPK as a 
regulator of MMP9 expression identifies a new target for treatment of vascular 
diseases like atherosclerosis. 
 
Patricia J. Gallagher Ph.D., Chair 
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Chapter I: Introduction 
 
Cardiovascular disease is the number one cause of death in the United 
States. Diseases such as atherosclerosis and restenosis following angioplasty 
can lead to death due to myocardial infarction and stroke. The determination of 
new therapies to prevent or halt the progression of these diseases is essential. 
The goal of the studies described in this dissertation was to characterize the role 
of death-associated protein kinase (DAPK) in vascular disease. The results of the 
studies presented here contribute to the accumulating knowledge of proteins and 
pathways that regulate the progression of vascular disease. 
 
Atherosclerosis: Roles of smooth muscle cells 
 Atherosclerosis is a disease that involves multiple cell types, including 
endothelial cells, macophages, lymphocytes, and smooth muscle cells (SMC) 
(80). Smooth muscle cells are known to play a key role in the development of 
atherosclerosis (reviewed in (31)). Even in utero at 36 weeks’ gestation, pre-
atherosclerotic lesions called eccentric intimal thickenings are found in human 
large arteries; these are present in nearly all humans by the age of 1 year (52, 
111, 122). These thickened regions generally consist mainly of SMCs and 
proteoglycans produced by these cells (111). These thickenings are of interest 
because the regions of the arteries where they tend to occur correlates with 
regions where advanced atherosclerotic lesions are found later in life (110, 111). 
Thus, inappropriate proliferation of SMC likely have roles in the early genesis of 
vascular disease (31). These roles include lipid uptake, maintenance of 
macrophage survival in lesions, and secretion of cytokines, extracellular matrix, 
and proteases.  
 SMC have several different characteristics and roles that are thought to 
contribute to atherosclerosis. A change in phenotype can often occur when the 
cells are exposed to an atherogenic environment in vivo (18, 90). SMC exhibit a 
switch from a “contractile” phenotype to a “synthetic” phenotype, when the cells 
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are exposed to stimuli like altered extracellular matrix (11, 115), cytokines (29, 
45, 77), shear stress (97), reactive oxygen species (113), and lipids (93). SMC 
are often exposed to such conditions during atherosclerosis, prompting the cells 
to decrease levels of smooth muscle contractile proteins like sm-α-actin, 
calponin, and smooth muscle myosin heavy chain, and to increase synthesis of 
collagen and other extracellular matrix proteins (90). The phenotypically 
“synthetic” cells also exhibit increased migration and proliferation. Inappropriate 
migration and proliferation of SMC has long been viewed a hallmark of vascular 
disease, and these altered, migratory and proliferative SMC likely contribute to 
the progression of atherosclerosis (90). In addition, receptors for VLDL and LDL 
increase during this phenotypic switch, leading to cholesterol uptake by SMC, 
turning these SMC into foam cells (75, 98, 101). In vitro culture models used in 
the studies in Chapter II allow for the addition and subtraction of growth factors to 
mimic the atherogenic stimuli that induce phenotypic switching. 
 SMC also play a role in the retention and survival of monocytes and 
macrophages in atherosclerotic lesions. Endothelial cells interact with monocytes 
as they are migrating into the intima, via expression of adhesion molecules like 
ICAM1 and VCAM1. These receptors are also expressed by SMC, and can 
mediate interactions with macrophages (12, 16, 112). Previous studies have 
found that VCAM1 and ICAM1 are expressed by intimal smooth muscle cells in 
human and mouse atherosclerotic coronary, aorta, and carotid arteries, but not in 
healthy medial smooth muscle (33, 57, 89). VCAM1 expression is found in lesion 
prone areas of arteries in the ApoE-/- mice, possibly indicating that its expression 
is important in the early generation of plaques (12). Blockade of VCAM1 with a 
neutralizing antibody leads to increased apoptosis of monocytes in a SMC-
monocyte co-culture model, indicating that these adhesion receptors promote 
survival of monocytes in vivo (16). Other pathways can also lead to increased 
monocyte binding to SMC, resulting in prevention of apoptosis (15). 
 SMC also produce cytokines, extracellular matrix, and proteases which 
may be important in atherogenesis. SMC produce PDGF, TGFβ, macrophage 
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inhibitory factor (MIF), interferonγ, and monocyte chemoattractant protein (MCP-
1) (4, 43, 84, 88, 92, 96). These cytokines, many of which are also produced by 
other cells in atherosclerotic plaques, can act in an autocrine fashion to induce 
ECM production. In addition, by acting in a paracrine fashion, many of these 
cytokines can induce endothelial dysfunction (96). SMC are the major producers 
of ECM in both healthy arteries and in atherosclerotic plaques (34). Type I and III 
collagen fibers make up the bulk of the ECM in healthy arteries; however, the 
atherosclerotic arteries contain increased proteoglycans, with some collagen I 
fibrils and fibronectin (99). This alteration in ECM allows atherosclerotic arteries 
to trap more LDL, leading to increased oxidized LDL, accelerated lesion 
progression, and cell proliferation (17, 19, 21). Also, the change from the fibrillar 
collagen found in healthy arteries to the proteoglycan and fibronectin rich plaques 
induces SMC to start proliferating; these proliferative SMC also increase 
production of proteoglycan, leading to increases in lesion size (17, 67, 100). Both 
SMC and macrophages produce matrix metalloproteinases; these will be 
discussed in the following section.  
  
Matrix metalloproteinase 9 and atherosclerosis 
 Several matrix metalloproteinases are found upregulated in atherosclerotic 
lesions, including MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP11, 
MMP12, MMP13, MMP14, and MMP16 (86). MMP2 and MMP9 are the two 
gelatinases that are secreted by SMC. These proteases can degrade a variety of 
substrates, including gelatin, collagen, fibronectin, laminin, and versican. MMP9 
can also degrade cytokines and chemokines, resulting in alteration of their 
activity (119). The importance of MMP9 in the regulation of smooth muscle cell 
migation has been well documented, both in vitro and in vivo (26, 38, 82). 
Incubation in conditioned media from rat aortic SMC overexpressing MMP9 led to 
increased SMC migration in vitro (82). Also, a study by Galis, et al. (2002) found 
that MMP9-/- mice showed impaired SMC migration in response to ligation of the 
carotid artery (38, 62). Results presented in Chapter II show that DAPK 
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negatively regulates expression of MMP9 in vitro in primary vascular smooth 
muscle cells, and Chapter III shows that DAPK promotes MMP9 expression in 
an  in vivo model. Tight regulation of MMP9 activity is important for maintainence 
of plaque stability. Expression of active MMP9 by macrophages resulted in 
plaque instability and disruption in ApoE-/- mice (41). This result implies that the 
role of DAPK as a regulator of MMP9 expression likely has important implications 
for vascular disease. 
 
Mouse models of atherosclerosis and vascular disease 
 Several mouse models exist for the study of atherosclerosis and vascular 
disease. Although there are disadvantages to mouse models, using a mouse 
model has the advantage of enabling the use of a variety of transgenic and gene 
knockout models, which are not extensively available for other species. 
Unfortunately, unlike humans, mice do not spontaneously develop large 
atherosclerotic lesions; small lesions similar to human fatty streaks can be 
induced by a high-fat/high-cholesterol diet (91, 114). Knockout approaches in 
combination with altered diet and/or vascular surgery are used to induce 
atherogenesis in mice (1, 65). The two main models of mouse atherosclerosis 
are the ApoE-/- mouse, and the LDLR-/- mouse (55, 94, 95, 130). Both of these 
models exhibit marked increases in serum cholesterol, especially when the mice 
are fed a high fat/high cholesterol diet, which results in the formation of complex 
atherosclerotic lesions. The high fat/high cholesterol diet accelerates the 
formation of the atheromas (65). Thousands of studies have been done over the 
last two decades using these atherosclerotic mice. 
 Vascular surgery is another way to induce atherogenesis in mice and 
other rodents (126). Several models exist to mimic injuries induced by 
angioplasty, including carotid artery catheter injury and femoral artery wire injury 
(79, 105). In addition, the carotid artery ligation surgery mimics vascular changes 
that occur as a result of blockage of an artery, resulting in thrombosis and altered 
shear stress (69). These three models have slightly varied results, in the type of 
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cells predominantly contributing to the lesions, and in the response to injury, but 
all of them generally result in SMC proliferation and migration, resulting in a 
thickened medial smooth muscle layer, and often the formation of a neointimal 
layer (126). Thus, these are accepted ways to test SMC migration and 
proliferation in vivo. The carotid artery ligation model was used to test the in vivo 
role of DAPK in chapters II and III. Atherosclerotic lesions often occur in humans 
at sites with altered shear stress; thus, the carotid ligation model mimics this 
situation (68). In addition, MMP9 is upregulated rapidly in the mouse carotid 
injury model, enabling in vivo studies of factors regulating its expression (40). 
Studies using mice deficient in MMP9 have revealed the importance of this 
vascular protease in the response to vascular injury (62). 
 
Regulation of MMP9 transcription and stability 
 The regulation of MMP9 transcription has been extensively studied in 
many cell types. As opposed to the constitutively expressed MMP2, the MMP9 
gelatinase is induced in vascular smooth muscle cells by a variety of cytokines, 
including TNFα, IL-1β, IL-4, IL-18, PDGF, and bFGF (reviewed in (87)). The 
MMP9 promoter has several well-characterized cis-regulatory elements, shown in 
Figure 1 including an AP1 binding site, an NF-κB binding site, and SP1 binding 
site (20, 76). The AP1, NF-κB, and SP1 binding sites are required for maximal 
MMP9 promoter activity in SMC and deletion of even one of these sites results in 
much lower induction of MMP9 by cytokines. In addition, steady-state levels of 
MMP9 can be regulated by signaling to stabilize the MMP9 mRNA, originating 
from α3β1 integrin (56). However, this regulation has not been verified in SMC. 
 
NF-κB signaling: overview and role of phosphorylation 
 The NF-κB transcription factor family contains five members, p65/Rel A, 
Rel B, c-Rel, NF-κB1 p105/p50, and NFκ−B2 p100/p52 (reviewed in (23, 46, 
85)). These proteins play important roles in a variety of cell processes, including 
apoptosis control, proliferation and differentiation. Specificity of signaling is 
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thought to occur via interaction of different combinations of homodimers and 
heterodimers, in conjunction with interactions with other transcription factors. 
While all the family members contain a Rel homology domain (RHD) required for 
DNA binding and dimerization, only the “Rel” proteins p65/RelA, Rel B, and cRel 
contain the transcription activation domain. Generally, heterodimers of one “Rel” 
protein (p65/RelA, RelB, or cRel) form with one non-TAD containing protein (p50 
or p52). The translocation of the dimers to the nucleus is regulated by the binding 
of several inhibitors of NF-κB (IκB), which both promote the nuclear export of p65 
and p50, and maintain p65/p50 and p65/p65 dimers in the cytosol. The canonical 
signaling involves activation that results in degradation of IκB induced by IκKβ, 
allowing the translocation of p65/p50 dimers to the nucleus to bind promoters and 
activate transcription(reviewed in (23, 46)). Other inhibitors of NF-κB signaling 
include the unprocessed, full-length NF-κB1 (p105) and NF-κB2 (p100). 
Cleavage of the inhibitory domains from p105 and p100 reveals the p50 and p52 
“active” versions. 
 The regulation of NF-κB also involves phosphorylation and acetylation of 
the family members (reviewed in (51)). Several phosphorylation sites on p65 
have been identified, and they exert a variety of effects that are still being 
characterized. Of interest to this dissertation is the phosphorylation of S536 on 
p65. This phosphorylated serine is located in the transactivation domain of p65, 
and has been reported to increase NF-κB activity. The mechanism behind this 
increase is likely to due to a conformation change that alters its interaction with 
other proteins. Notably, p65 phosphoS536 exhibits decreased affinity for IκB. 
This leads to an inability of IκB to export p65 phosphoS536 from the nucleus (10, 
13, 39). In addition, p65 phosphoS536 has increased binding to the histone 
acetyltransferase p300, and decreased binding to the SMRT and HDAC3 co-
repressors (24, 47). Several kinases can mediate this phosphorylation, including 
IκKα/β and RSK1(102, 103). Results presented in Chapter II reveal an indirect 
role for DAPK in regulation of p65 phosphorylation on S536. 
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Death-associated protein kinase 
 Death-associated protein kinase-1 (DAPK) is a 160-kD serine/threonine 
kinase. As its name implies, the human DAPK1 cDNA was originally cloned as a 
gene that contributes to interferon-γ induced cell death (30). At the same time, 
the Gallagher lab cloned the mouse DAPK1 cDNA based on the high degree of 
homology between kinase domain of DAPK and myosin light chain kinase 
(MLCK) (58). DAPK is part of a family of death-related kinases; other family 
members include DAPK-1-related protein 1 (DRK1 or DAPK2), zipper interacting 
kinase (ZIPK or DAPK3), DAP-kinase related apoptosis inducing protein kinase 1 
(DRAK1) and DRAK2 (9). The kinases in this family do share highly similar 
kinase domains, but the other domains in these proteins give them unique 
functions in vivo. DAPK1 (referred to as DAPK in this dissertation) is the most 
well studied member of this family, and is the focus of the experiments described 
in the subsequent chapters.  
 DAPK has been implicated in a variety of cellular functions, including 
regulation of apoptosis, autophagy, survival, cell migration, and adhesion (9, 58, 
61, 71, 121, 128). DAPK has been proposed to be a tumor suppressor, after 
findings indicated that methylation of the DAPK promoter was linked to cancer 
recurrence and metastasis (9). Many early studies linked the kinase activity of 
DAPK to the promotion of apoptosis and autophagy. However, many of these 
reports were performed using cells overexpressing a constitutively active form of 
DAPK which can induce morphological changes that cause cells to round and 
detach from the extracellular matrix (121). More current studies, using siRNA 
depletion of DAPK and other strategies, have identified non-death related roles 
for the protein (78).  
DAPK has several domains that mediate protein-protein interactions with a 
variety of proteins. The domains include an N-terminal kinase domain, a 
calmodulin (CaM) binding domain, a series of eight ankyrin repeats, two P-loops, 
a cytoskeletal binding domain, and a death domain (Figure 2). Previous studies 
have found that the non-kinase domains are important in mediating interactions 
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with other proteins and also for regulation of kinase activity; in fact, most of the 
proteins that have been shown to bind to DAPK are not substrates of the kinase 
(78). The experiments in this dissertation used strategies such as siRNA 
knockdown and genetic ablation of DAPK to further examine the physiological 
role of DAPK in the smooth muscle cells of the vasculature. Thus, the focus was 
on deletion of the protein as a whole, and not specifically on the kinase activity, 
so only a few of the 11 substrates of DAPK will be highlighted here. First, DAPK 
is a substrate for itself and undergoes autophosphorylation at S308 (Figure 2). 
This phosphorylation site lies within the calmodulin binding region, and blocks 
activation of the kinase by inhibiting binding of the activator Ca2+/calmodulin to 
the region (60, 109). Dephosphorylation of this site by PP2A represents part of 
the mechanism by which DAPK is activated in response to detachment induced 
cell death, or anoikis (123). Another well-characterized substrate of DAPK is 
myosin regulatory light chain (MLC) and phosphorylation of MLC activates 
myosin II motor activity leading to force generation needed for cell migration, 
shape changes, and cell division (7, 28, 58). Other proposed substrates include 
beclin-1, CaMKK, MCM3, p21, p53, S6, syntaxin-1A, tropomyosin-1, and ZIPK 
(6, 36, 48, 107-109, 116, 128).  
Many proteins that interact with DAPK have been identified. Relevant to 
this dissertation are actin, MCM3, Mib1, PP2A, ERK, PKD, and RSK and these 
interactions will be briefly discussed (2, 6, 7, 22, 27, 28, 59, 123).  
Early studies linked DAPK and actin, after limited biochemical studies 
showed that DAPK co-fractionates with actin in a RIPA lysate pellet (28). In this 
study, treatment of cells with Latrunculin A to inhibit actin polymerization resulted 
in an increase in the soluble DAPK, although at least half of the DAPK was still 
insoluble, while most of the actin was solubilized by Latrunculin A. Also, 
immunofluorescence performed on cells transfected with GFP-DAPK showed 
that the exogenous protein localized to the cytoskeleton. From these 
experiments, it was inferred that DAPK is a cytoplasmic, actin-bound protein, and 
that a cytoplasmic region is required for this interaction (28). Data that will be 
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presented in Chapter II contradict this finding and suggest that some of the 
DAPK is present in the nucleus. Supporting this statement is the recent 
identification of a novel DAPK substrate, the nuclear protein mini-chromosome 
maintenance complex component 3 (MCM3) (6). 
Two E3 ubiquitin ligases that interact with DAPK are DAPK-interacting 
protein 1/Mindbomb1 (Mib1) and Carboxyl terminus of HSC70-interacting protein 
(CHIP) (59, 129). Studies have characterized roles for these E3 ligases in 
regulation of DAPK levels via ubiquitination and proteasomal degradation; 
however, these ligases may also have other roles that involve interaction and 
targeting by DAPK binding.  
DAPK has been proposed to be involved in the regulation of several 
signaling pathways, including MAPK family members ERK and JNK, and NF-κB 
based on interactions with proteins such as ERK, protein kinase D (PKD), and 
PKC-θ. Previous studies have found that DAPK and ERK can phosphorylate 
each other, and that DAPK activity blocks the nuclear translocation of ERK in 3T3 
cells (22). DAPK can also promote oxidative stress-induced JNK activation in 
HEK293 cells, via phosphorylation of PKD (32). Finally, DAPK blocks nuclear 
accumulation of NF-κB family member p65/RelA in T cells through regulation of 
PKC-θ, in response to T cell receptor activation, but DAPK does not does affect 
NF-κB signaling in response to TNFα in T cells (27). 
DAPK has been previously linked to atherosclerosis by two studies, which 
found increased DAPK in and around atherosclerotic lesions (81, 124). The goal 
of the studies presented in this dissertation was to characterize the role of DAPK 
in smooth muscle cells, and determine how its expression affects vascular 
pathology. Based on studies showing that DAPK is upregulated in atherosclerotic 
plaques, and can regulate cell migration, I propose that DAPK regulates SMC 
signaling and migration. Studies in Chapter II will examine the effect of siRNA 
depletion of DAPK from primary smooth muscle cells. Chapter III will explore the 
role of DAPK in vivo, using a newly produced DAPK KO mouse model.
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Figure 1: MMP9 promoter cis regulatory elements. 
The MMP9 promoter contains the following conserved cis elements: an NF−κΒ  
binding site (-600), an AP1 binding site (-73) and an SP1 binding site at (-48). 
Adapted from (20, 76).  
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Figure 2: The domains of DAPK. 
Schematic showing domains in DAPK, including the N-terminal ser/thr kinase 
domain, a Ca2+/calmodulin binding domain which contains an auto-phosphoryla-
tion site at ser308, a series of 8 ankyrin repeats, 2 P-loops, a cytoskeletal-binding 
domain, and a death domain. 
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Chapter II: DAPK Blocks MMP9 Expression in Vascular Smooth Muscle 
Cells Via Indirect Regulation of NF-κB p65 Phosphorylation 
 
Introduction 
Inappropriate proliferation and migration of vascular smooth muscle cells 
contributes to the pathogenesis of many vascular diseases including 
atherosclerosis and restenosis (31). Many signaling pathways play a role in 
smooth muscle cell survival, migration, and proliferation, but our understanding of 
the regulation of these pathways is incomplete. Further knowledge of the 
regulation of these pathways will lead to better treatments of vascular disease.   
 Death-associated protein kinase 1 (DAPK or DAPK1) is a 160 kDa serine-
threonine kinase which is regulated by Ca2+/calmodulin binding (9, 58). Several 
studies have elucidated a role for DAPK in human cancers, and it has been 
proposed to be a tumor suppressor (64). DAPK overexpression can promote 
autophagy in some cells and also can regulate apoptosis (53, 128); the effect, 
however, is cell type and context dependent (8, 78). Several studies have also 
identified a role for DAPK as a negative regulator of cell adhesion and migration, 
however these studies have been performed in cancer cells and fibroblasts (70, 
71, 121, 123). While DAPK is expressed in smooth muscle cells, and cell 
adhesion and migration are important roles of smooth muscle cells in the genesis 
of vascular disease, the role of DAPK in vascular smooth muscle cells has not 
been well studied. Two previous studies have identified increased levels of DAPK 
in regions of arteries containing atherosclerotic lesions (81, 124). However, these 
studies have not characterized the functional role of DAPK in vascular disease. 
Based on the previous work, we hypothesized that DAPK negatively regulates 
SMC migration. 
 In the current study, we used a focused RT-PCR based array to identify 
genes regulated by endogenous DAPK that could be regulating cell migration. 
This lead to the discovery that DAPK negatively regulates transcription of matrix 
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metalloproteinase 9 (MMP9) in primary smooth muscle cells via regulation of NF-
κB family member p65. 
 
Materials and Methods 
Cells, Antibodies, and Reagents. Human coronary artery smooth muscle cells 
(HCASMC) are purchased from Lonza and were cultured as previously described 
(131). SMC growth media used was MCDB131 containing 5% FCS, 2 ng/ml 
human bFGF, 5 mg/ml human insulin, and 0.5 ng/ml human EGF. EGF, insulin, 
and bFGF were obtained from Invitrogen. HeLa cells were purchased from ATCC 
and were cultured in DMEM (Mediatech) containing 10% FCS and glutamine and 
penicillin/streptomycin (Mediatech). HeLa cells were transfected using Fugene 6 
(Roche), following the manufacturer’s protocol. Monoclonal antibodies to DAPK 
(clone 55), sm-α-actin (A2547), calponin (clone hCP) and vinculin were obtained 
from Sigma. Antibodies to MMP9, p65 phosphoS536, p65 phosphoS276, total 
p65, phospho-ERK, phospho-p38 MAPK, P- IκKα/β S176/S180, NF-κB1, NF-
κB2, Rel B, and c-Rel were obtained from Cell Signaling Technology. GAPDH 
monoclonal antibody was purchased from Novus. Human DAPK siRNA was 
obtained from Dharmacon (D-004417-07) and p65/Rel A siRNA was purchased  
from Qiagen (SI00301672). The sequence of the double-stranded, nontargeting 
control siRNA was 5’-GAU GAC AGG UAU AGU AAG UUU-3’, and was 
purchased from Dharmacon. TNFα, U0126, SP600125, and SB203580 inhibitors 
were purchased from EMD Biosciences. All other reagents were purchased from 
Fisher Scientific unless otherwise noted. 
 
Nucleofections. Nucleofections were performed per the manufacturer’s protocol 
for primary smooth muscle cells (Lonza, VPI-1004; Nucleofector II device). For 
Nucleofections of primary HCASMC, 80% confluent cells were trypsinized and 
pelleted. Each sample consisted of 1 x 106 cells and was resuspended in 100 µl 
of Nucleofection reagent and then mixed with either 4 µl 40 µM siRNA or 2-5 µg 
plasmid DNA. Cells were then nucleofected using program P-24. Cells were 
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immediately transferred to tubes containing SM-2 media (Lonza), and then 
cultured at 37°C in 5% CO2 for 24-72 hours before analysis. Transfection 
efficiency was determined to be greater than 95% for siRNA using siGlo control 
siRNA (Dharmacon), and approximately 40% efficient for cDNA, as indicated by 
nucleofection of GFPmax cDNA (Lonza). 
 
ApoE-/- mice. All animal studies followed the guidelines for care of animals at 
Indiana University and were approved by Indiana University IACUC. For the IHC 
studies, two-month old control, male C57BL/6 were obtained from Harlan and 
ApoE-/- mice were purchased from Jackson Laboratories. The mice were fed a 
Western diet containing 0.21% cholesterol and 21% fat (D12097B; Research 
Diets) for 3 months, anesthetized with a cocktail of ketamine (0.1 mg/g) and 
xylazine (0.01 mg/g), and aortas were harvested from the mice. For 
immunohistochemistry, mice were perfused with PBS and then by 4% 
paraformaldehyde in PBS. Aortas were fixed overnight in 4% paraformaldehyde, 
paraffin embedded, and sectioned. For RNA analysis, 6-month old ApoE-/- mice 
were obtained from both Jackson Laboratories and an internal colony of ApoE-/- 
mice, and were fed a Western diet for 2 months. The mice were anesthetized and 
perfused with PBS followed by RNAlater (Ambion). Aortas were stored in 
RNAlater at 4°C and then dissected under a dissection microscope, separating 
regions with white, visible plaques from plaque-free regions. Samples were 
frozen at -80°C, and RNA was prepared using Trizol after grinding tissue in a 
Pyrex glass tissue grinder. 
 
Immunohistochemistry. Sections from paraffin-embedded aortas were 
rehydrated and antigens retrieved using a Retriever 2100 and R-Buffer UG 
(Electron Microscopy Services). Sections were stained with DAPK (1:75, Sigma, 
DAPK-55) and sm-α-actin (1:500, Sigma) antibodies overnight using the M.O.M. 
peroxidase kit and the NovaRed peroxidase substrate kit (both from Vector 
Laboratories). Negative controls included no primary antibody. Masson’s 
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Trichrome staining was performed by the Indiana University Anatomy and Cell 
Biology Histology Core. Images were obtained from a Nikon Diaphot 200 
microscope, and Olympus DP70 camera using Plan 10x Nikon objective and 
were compiled in Adobe Photoshop. All images were treated identically. 
 
Carotid artery injury model. Eight-week old C57BL/6 mice underwent the 
carotid ligation surgery as previously described (69). Briefly, mice were 
anesthetized with a cocktail of ketamine (0.1 mg/g) and xylazine (0.01 mg/g). The 
carotid artery was exposed via a 0.5-cm incision 1-mm from the midline on the 
mouse’s neck. A 4-0 silk suture was used to ligate the right common carotid 
artery, proximal to the bifurcation. Mice were sacrificed 4-14 days following injury, 
and the injured carotid artery rinsed in PBS and frozen in liquid nitrogen. 
Uninjured carotid arteries from mice that did not undergo surgery were used as 
controls. Lysates were prepared by grinding the frozen arteries in RIPA buffer 
containing protease and phosphatase inhibitors (Sigma) using a glass tissue 
homogenizer.  
 
Migration assays. Modified Boyden chamber assays were performed by plating 
50,000 cells per cell culture insert (8 µm pore size #353097; BD Biosciences). 
Inserts were placed in 24-well culture dishes containing MCDB131 plus 10% FCS 
in the lower well. After 6 hours of incubation, cells remaining on the upper side of 
the membrane were removed with a cotton swab, and migrated cells on the 
bottom side were fixed in 3.7% formaldehyde and stained with 0.4% crystal violet 
in 20% methanol. After briefly destaining in water, transwells were photographed 
and cells counted. Five fields were counted per transwell, and three transwells 
were used per condition for each experiment. Migration index was calculated by 
normalizing the number of cells migrated in test samples to cells migrated in 
control samples. 
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Superarray analysis. HCASMC nucleofected with control or DAPK siRNA were 
serum starved for 2 days in MCDB131 media. RNA was purified using Trizol and 
then treated with DNase I (Roche) to remove genomic DNA. cDNA for 
Superarray analysis was prepared using RT2 First strand cDNA Synthesis Kit 
(SABiosciences). RT-PCR was performed RT2 qPCR SYBR green Master Mix 
and the human Extracellular Matrix and Adhesion Molecules PCR Array (PAHS-
013; SABiosciences).  Data was analyzed using the SABiosciences protocol.  
 
Real-time RT-PCR. RNA was prepared from cells or tissues using Trizol 
(Invitrogen). 0.5 µg was reverse transcribed as previously described (131). cDNA 
was diluted 1:5 with water, then amplified using Faststart SYBR green master 
mix (Roche) and gene specific primers (Eurofins MWG/Operon) in a AB 7500 
Real-Time System (Applied Biosystems). Relative abundance of mRNA was 
calculated using the 2-ΔΔCt method. HPRT was used as an internal control for 
human RNA, and RPLPO was used as an internal control for mouse RNA. Primer 
sequences used are listed in Table 1. 
 
Immunoblotting. Cells were lysed in RIPA lysis buffer containing protease 
inhibitor cocktail and phosphatase inhibitor cocktails 1 and 2 (Sigma). Protein 
was quantitated using a BCA assay (Pierce).  Cytosolic and nuclear fractions 
were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents 
(Pierce). Equal amounts of proteins were separated by SDS-PAGE, and detected 
using standard immunoblotting protocols. Immunoblots were imaged using a 
Syngene G-box and GeneSnap software (Synoptics). Quantitation of band 
intensity was performed using ImageJ (NIH). 
 
Gelatin zymography. Zymography was performed as previously described with 
a few modifications (73). Briefly, to generate conditioned media, equal numbers 
of cells were plated in 6 well plates. Cells were serum starved in MCDB 131 
(Mediatech) for 24 to 48 hours, and conditioned media was collected and 
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concentrated 50x using Ultracel-10K centrifugal filters (Amicon). Volumes of 
concentrated media were normalized to the amount of protein contained in the 
RIPA lysates, to compensate for variations in cell number. Media samples were 
separated by SDS-PAGE containing 7.5% acrylamide and 0.1% gelatin (BioRad). 
Gels were incubated in 2.5% Triton-X-100 for 30 minutes, then incubated in 
zymography buffer overnight at 37°C. (50 mM Tris pH 7.5, 200 mM NaCl, and 5 
mM CaCl2). Gels were stained in 0.5% Coomassie Blue R-250 in 7.5% 
methanol/7.5% acetic acid for 24 hours, followed by destaining in 7.5% 
methanol/7.5% acetic acid for 2 hours. Gels were dried and photographed using 
a Syngene GeneSnap imager.  
 
Promoter assays. MMP9 promoter constructs (WT and mutAP-1) used in this 
study were the kind gift of Dr. Bysani Chandrasekar (University of Texas-San 
Antonio) (20), and were in pGL3b (Promega). The MMP9 mut-NF-κB construct 
was generated in this laboratory using site-directed mutagenesis of the NF-κB  
binding site using the Quikchange Site-Directed mutagenesis kit (Stratagene). 
Primers used were: forward (GGG GGT TGC CCC AGT GGC CTT TTC CAG 
CCT TGC CTA GCA G) and reverse (CTG CTA GGC AAG GCT GGA AAA GGC 
CAC TGG GGC AAC CCC C). The NF-κB-Luc plasmid was purchased from 
Stratagene. The p65 WT, S536A, and S536D mutant cDNAs were the kind gift of 
Dr. Carl Sasaki (NIH) (104). Primary HCASMC were Nucleofected with siRNA, 
and then plated and incubated at 37°C to allow siRNA to deplete target RNA. 
After 3 days, cells were Nucleofected again with MMP9 and NF-κB-luciferase 
cDNA constructs and plated in four wells of a 24-well plate in Lonza SM-2 growth 
media. One well was lysed in Laemli sample buffer and used to confirm protein 
expression and knockdown by immunoblotting. Three wells were lysed 18 hours 
after Nucleofection in Passive Lysis Buffer (Promega) containing protease 
inhibitor cocktail (Sigma), and assayed for Luciferase activity as previously 
described (131). Luciferase values were normalized to TK-Renilla (Promega).   
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Data analysis. All experiments were independently performed at least three 
times. All statistical analysis and graphs were created using GraphPad Prism 
software (GraphPad Software, San Diego, CA). Graphs display mean +/- sem of 
at least three independent experiments unless otherwise noted. Statistical 
significance was determined by Student’s t test unless otherwise noted. 
 
Results 
To better understand the role of DAPK in vascular tissues, the expression 
pattern of DAPK in atherosclerotic lesions in the well-characterized ApoE-/- mouse 
model of atherosclerosis was examined. Paraffin sections of aortas from wild-
type control and ApoE-/- mice fed a Western diet were stained for DAPK or sm-α-
actin, and then examined for expression. Figure 3A shows a representative 
image from the aortas, revealing an increase in DAPK expression in the 
atherosclerotic plaque from the ApoE-/- mice, compared with the wild type control. 
Immunostaining of adjacent serial sections of atherosclerotic plaques shown in 
Figure 3A to detect expression of sm-α-actin, revealed that the areas of plaques 
with the greatest DAPK expression coincided this smooth muscle marker. Using 
RT-PCR the relative levels of DAPK mRNA were then quantitated in plaque 
versus non-plaque regions of aortas from ApoE-/- mice that had been fed a 
Western diet for 2 months. Figure 3B reveals that DAPK mRNA is significantly 
increased in plaque regions compared to non-plaque regions of the aortas. In 
addition to the atherosclerosis model, the carotid ligation model was also utilized 
to examining the expression of DAPK. Immunoblotting of tissue lysates from 
injured or uninjured control carotid arteries, revealed that DAPK protein was 
significantly upregulated as early as 4 days after injury, with peak levels observed 
by 7 days post-injury and this high level of expression was maintained for at least 
2 weeks (Figure 3C). These data indicate that expression of DAPK is increased 
in two mouse models of vascular pathology and suggest a potential link to the 
development of vascular disease.  
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Smooth muscle cells are unique in that they can alter their phenotype 
depending on the conditions used to culture the cells (90). In the presence of 
serum and growth factors, the cells are more secretory, migratory, and 
proliferative, and they express less of the smooth muscle contractile proteins. 
Serum starvation induces a more differentiated state, with decreased secretion, 
migration and proliferation, and increased expression of smooth muscle marker 
proteins such as sm-α-actin, calponin, and sm22α. Figure 4A shows an 
immunoblot of lysates from primary human coronary artery smooth muscle cells 
cultured in either growth media, or serum-free media for up to 8 days. The results 
show that DAPK expression increased in parallel with the smooth muscle 
markers. This finding is consistent with our in vivo results, indicating that DAPK is 
expressed in more differentiated smooth muscle cells.  
DAPK has been implicated in the regulation of cell migration in 3T3 
fibroblasts and cancer cells (71). This observation prompted studies to determine 
whether DAPK regulates migration of smooth muscle cells. Nucleofection was 
used to introduce DAPK cDNA into the primary human coronary artery smooth 
muscle cells (HCASMC), and then the ability of these cells to migrate in a 
modified Boyden chamber assay was tested. As is seen in Figure 4B, 
overexpression of DAPK significantly reduced (43.0 +/- 8.0% of control) the 
ability of HCASMC to migrate toward the serum stimulus. Conversely, when 
Nucleofection of DAPK siRNA was used to deplete DAPK from the primary 
smooth muscle cells, the migration of primary HCASMC was augmented (Figure 
4C; 45.4 +/- 11.3% increase over control). A representative immunoblot 
confirmed the overexpression of DAPK, and also shows that DAPK siRNA 
depletion was efficient (Figure 4D). These results indicate that DAPK is a 
negative regulator of smooth muscle cell migration. 
DAPK has been shown to regulate many different cellular signaling 
pathways in other cell types, but the role in regulation of vascular smooth muscle 
migration is undefined. We hypothesized that alteration of DAPK protein levels in 
smooth muscle cells caused a change in signaling pathways, resulting in altered 
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transcription of downstream genes. A focused RT-PCR based screen of 
extracellular matrix and adhesion molecules was performed to identify genes 
related to cell migration that may be regulated by DAPK signaling, and ultimately 
the pathways DAPK impacts in primary smooth muscle cells.  In this screen, the 
mRNA levels of extracellular matrix (ECM) and adhesion genes were compared 
in control and DAPK-depleted HCASMCs. Several genes were identified that 
were altered in response DAPK depletion including MMP9, E-cadherin, VCAM1, 
β3-integrin, PECAM1, TIMP3, ADAMTS8, CTGF, CLEC3B, and laminin α3. One 
of the targets, matrix metalloproteinase 9 (MMP9), a cytokine-inducible protease, 
was selected for further validation based on its link to cell migration and vascular 
pathology(87). In our screen, we found that MMP9 was increased 3.6-fold in 
HCASMC depleted of DAPK. In order to verify that MMP9 is increased in 
HCASMC, we examined MMP9 mRNA expression in HCASMC both in the 
presence and absence of serum.  As is shown in Figure 5A, DAPK depletion 
leads to a 49.3 +/- 22.9% increase in MMP9 mRNA under growth conditions (plus 
serum and growth factors). The increase in MMP9 is more apparent in the 
serum-starved condition, when the absence of DAPK results in a 166 +/- 28% 
increase in MMP9 mRNA (Figure 5A). Under these conditions, we also validated 
a change in VCAM1, which was upregulated by 140 +/- 9% in DAPK-depleted 
cells in serum-free media, compared to control cells (Figure 5B). We also 
examined MMP9 protein levels in concentrated, conditioned media from 
HCASMC depleted of DAPK using both immunoblotting and gelatin zymography, 
which in-gel digestion of gelatin from MMP9 protein in samples results in light 
areas on a dark background after staining of the gel. The intensity of the light 
areas correlates with MMP9 levels in the conditioned media. This data revealed 
that depletion of DAPK in HCASMC caused an increase in the amount of MMP9 
protein secreted (Figure 5C, lane 2). Conversely, overexpression of DAPK 
(Figure 5C, lane 3) suppressed MMP9 protein expression. Finally, rescue of 
DAPK expression by Nucleofection of DAPK cDNA in HCASMC previously 
depleted of DAPK, partially restored MMP9 secretion (Figure 5C, lane 4). Thus, 
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DAPK negatively regulates MMP9 mRNA and secreted MMP9 protein in 
HCASMC.  
Previous reports have found that the steady-state levels of MMP9 mRNA 
can be altered by changes in the stability of the mRNA, involving signaling from 
integrin pathways (56). In order to determine if DAPK negatively regulates the 
stability of MMP9 mRNA in HCASMC, an RNA stability assay was performed. 
The mRNA levels of MMP9 were measured in control and DAPK-depleted 
HCASMC after treating the cells with the transcription inhibitor Actinomycin D for 
8-24 hours. MMP9 mRNA levels were normalized to levels found in control cells 
treated in parallel with the vehicle, DMSO. As is shown in Figure 5D, there was 
no significant difference in the stability of MMP9 mRNA in control or DAPK-
depleted HCASMC, either in growth conditions or in serum-free media. It is 
interesting to note that the presence of serum and growth factors did markedly 
stabilize MMP9 mRNA, with no degradation measured after 24h of Actinomycin D 
treatment (Figure 5D). Comparatively, HCASMC grown in the absence of serum 
exhibited a drastically reduced half-life of approximately 8 hours. Thus, while the 
presence of growth factors strongly stabilizes MMP9 mRNA, expression of DAPK 
does not affect the stability of MMP9 mRNA. 
Since DAPK does not alter the stability of MMP9 mRNA, it likely acts by 
attenuating MMP9 promoter activity. MMP9 is an inducible gene that is regulated 
by cytokines via many signaling pathways in vascular smooth muscle cells, 
including the MAPK pathways (25). In order to determine if the increase in MMP9 
that we observe in HCASMC depleted of DAPK is due to increased MAPK 
signaling, DAPK-depleted HCASMC were treated with inhibitors of ERK (U0126), 
JNK (SP600125) or p38 MAPK (SB203580), and the effect on MMP9 expression 
was measured by qRT-PCR. As is shown in Figure 6A, while DMSO-treated, 
DAPK-depleted HCASMC exhibited a 2.7-fold increase in MMP9 expression, this 
increase in MMP9 expression was not significantly affected by treatment of 
HCASMC with these MAPK inhibitors. Thus, the increase in MMP9 expression 
following DAPK depletion is not due to increased MAPK signaling. 
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In order to directly determine the effect of DAPK on the MMP9 promoter, 
promoter assays were performed using a previously described luciferase 
construct containing a 726-base pair region flanking the 5’ end of the human 
MMP9 gene (20). This region of the MMP9 promoter is responsive to cytokines 
such as TNFα, and contains well-characterized cis-elements, which bind NF-κB 
and AP-1 transcription factors. Using Nucleofection to introduce the promoter 
construct into previously DAPK-depleted or control HCASMC, we found that 
DAPK depletion significantly increased MMP9 promoter activity (Figure 6B). To 
further determine the regulatory elements and pathways required for the DAPK 
effect, previously characterized promoter constructs containing point mutations at 
either the NF-κB binding site, or the AP-1 binding site were used. While mutation 
of the AP-1 binding site in the MMP9 promoter did not alter the effect of DAPK 
depletion, mutation of the NF-κB binding site blocked the effect of DAPK 
depletion on the MMP9 promoter (Figure 6B). Thus, the NF-κB binding site is 
required for the increase in MMP9 promoter activity observed when DAPK is 
depleted from HCASMC. As expected, the luciferase activities generated in 
response to the mutant AP-1 and mutant NF-κB sites were much lower than 
those generated from the wild-type MMP9 constructs, although they have 
detectable activity above empty pGL3b controls (data not shown). In addition, we 
directly tested the effect of DAPK on activation of a synthetic luciferase construct 
whose expression is driven by consensus κB binding elements. The NF-κB-Luc 
construct exhibited greater activation in HCASMC depleted of DAPK (Figure 6B). 
Thus, DAPK negatively regulates MMP9 expression via decreased NF-κB 
signaling. 
The NF-κB signaling pathway is composed of 5 main family members: 
p65/Rel A, Rel B, c-Rel, NF-κB1 p105/p50, and NF−κB2 p100/p52. They form 
homodimers and heterodimers to activate transcription (23, 46). Much of the 
regulation of canonical NF-κB signaling occurs via maintenance of p65 in the 
cytosol by binding of inhibitors, such as IκBα. Upon stimulation, the inhibitors are 
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phosphorylated by IκKβ and degraded, allowing p65/p65 and p65/p50 dimers to 
translocate to the nucleus to activate transcription on NF-κB responsive genes. 
As the increase in MMP9 promoter activity was observed only when NF-κB 
binding site was intact, the possibility that DAPK might be altering the amount of 
p65 in the nucleus under basal conditions was examined. For this experiment, 
the levels of p65 in cytosolic and nuclear fractions from control and DAPK-
depleted HCASMC were determined by immunoblotting. These results showed 
the expected increase in nuclear p65 in response to TNFα treatment (Figure 7, 
lanes 5 and 6); however, there was no significant difference in nuclear p65 levels 
following TNFα stimulation in control compared to DAPK-depleted cells (Figure 
7, lanes 6 and 8). In addition, there was no difference in nuclear p65 under basal 
conditions (Figure 7, lanes 5 and 7). Finally, there were no changes in the levels 
of NF-κB1, NF-κB2, RelB, and c-Rel either in the cytosol or nuclear fractions 
(Figure 7). Interestingly, DAPK was predominantly found to be localized to 
nuclear fractions in control siRNA-treated HCASMC (Figure 7), although the 
significance of this finding is unclear.  
Recently, the importance of post-translational modification of NF-κB-p65 
(p65) has become appreciated (51). One site that has been shown to be 
important in the regulation of p65 localization and transcriptional activity is serine 
536 (24, 47, 49, 102, 103). After finding that there was no change in the amount 
of total p65 in the nucleus, the amount of phosphorylated-S536 p65 (p65 
phosphoS536) in control and DAPK-depleted cells was determined using a p65 
antibody that specifically recognizes p65 phosphoS536 (Figure 8A). This 
experiment showed that a 44 +/- 16% increase in phosphorylation at p65 
phosphoS536 was detected in HCASMC depleted of DAPK (Figure 8B). These 
results suggest that DAPK negatively regulates the phosphorylation of p65 at 
serine 536. 
Some previous studies have suggested that p65 phosphoS536 increases 
the propensity for p65 to be retained in the nucleus (10, 13). Others suggest that 
p65 phosphoS536 alters the transcriptional activity of NF-κB, since S536 is 
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located within the transactivation domain of p65 (24, 47). To determine the effect 
of p65 phosphoS536 in primary HCASMC, these cells were first depleted of 
endogenous p65 by transfection with siRNA specific to p65. Subsequently, the 
p65-depleted cells were transfected with vectors for expression of wild-type p65, 
the phosphomimetic mutant, p65-S536D (serine to aspartic acid mutation) or the 
nonphosphorylatable mutant, p65-S536A (serine to alanine mutation). The effect 
of these transfected p65 proteins on a co-transfected NF-κB-Luc construct was 
then determined. As shown in Figure 9A, siRNA depletion of p65 was efficient in 
decreasing in NF-κB dependent promoter activity (approximately 50% decrease), 
which could be rescued by expression of wild-type p65 or the 
nonphosphorylatable mutant. The phosphomimetic mutant, p65-S536D showed 
50% more NF-κB activity. These results indicate that S536 phosphorylation 
makes an important contribution to NF-κB transcriptional activity in primary 
HCASMC. Western immunoblotting confirmed that p65 was efficiently depleted 
from HCASMC (approximate 75% decrease) and that the relative expression 
levels of the transfected p65 wild type or mutant constructs while low, were 
similar (Figure 9B). Because the expression of the rescued protein was near the 
limit of detection in HCASMC, the expression levels of the constructs was also 
verified in HeLa cells and found to be similar (Figure 9C). 
Based on the collective findings that DAPK depletion from HCASMC does 
not alter the level of nuclear p65 (Figure 7), increases the level of p65 phospho-
S536 (Figure 8), and that p65 phosphoS536 enhances NF-κB activity (Figure 9), 
the relative levels of TNFα-stimulated p65 phosphoS536 in the nucleus following 
DAPK depletion were determined. These results revealed that there is a two-fold 
increase in the amount of TNFα-stimulated nuclear p65 phosphoS536 in DAPK-
depleted cells, as compared with control cells (Figure 10A, lanes 6 and 8). Thus, 
although DAPK depletion does not change the amount of total p65 translocated 
to the nucleus, it does result in an increase in p65 phosphoS536. It should be 
noted that in the absence of TNFα stimulation nuclear p65 phosphoS536 is not 
detectable.  
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This data indicates that phosphorylation of p65 at S536 may have a role in 
regulating the amount of nuclear p65 available to activate transcription of genes 
like MMP9, and that DAPK regulates this phosphorylation. To determine if p65 
expression was required for the increased NF-κB binding and increased MMP9 
promoter activity observed in the DAPK-depleted HCASMC, siRNA was used to 
deplete endogenous DAPK and/or p65 from HCASMC. The effects of these 
depletions on NF-κB-regulated MMP9 promoter activity were measured using 
luciferase reporter assays. In these experiments, the results were normalized to 
either control siRNA alone, or p65 siRNA alone to specifically determine whether 
or not p65 was required for the increased activity observed when DAPK is 
depleted. As is shown in Figure 10B, depletion of DAPK led to an increase in the 
NF-κB promoter activity and this effect was attenuated when both p65 and DAPK 
were depleted from HCASMC. A similar trend was observed with the MMP9 
promoter; DAPK depletion resulted in a slight increase in promoter activity, and 
the increase was blocked when both DAPK and p65 were depleted (Figure 10B). 
These results indicate that the increase in MMP9 promoter activity observed 
when DAPK is depleted from primary HCASMC likely requires p65, and probably 
occurs in response to increased phosphorylation of p65 at S536.  
The increase in phosphorylation observed could be due to increased 
kinase activity by IκKα/β, which are known to phosphorylate p65 at S536. 
However, immunoblotting (Figure 10C) for the activated, phosphorylated IκKα/β 
was not different between control and DAPK depleted HCASMC, indicating that 
the p65 phosphoS536 is increased by another unknown mechanism. 
 
Discussion 
While previous studies have enhanced our understanding of the pathways 
regulated by DAPK and potential substrates for this protein kinase, these studies 
have focused on examining the role of DAPK in cancer cells, fibroblasts, and 
immune cells (22, 27, 32, 58, 71). The results presented here are unique in that 
they are the first to characterize the role of DAPK in primary vascular smooth 
  26 
muscle cells. Using a focused RT-PCR based array, we have found that DAPK is 
a negative regulator of several genes linked to migration and extracellular matrix 
composition, including MMP9. The current study focused on the role of DAPK in 
regulation of MMP9, and our results demonstrated that there is a diminished 
secretion of MMP9 protein when DAPK is overexpressed, and enhanced MMP9 
protein and mRNA when DAPK is depleted from primary HCASMC. 
Mechanistically these studies show that DAPK mediates its transcriptional 
regulation by blocking NF-κB activity. This finding is supported by results 
showing that mutation of a cis element in the MMP9 promoter that binds NF-κB 
blocks the effect of DAPK on this promoter. In addition, DAPK depletion from 
HCASMC results in increased nuclear p65 phosphoS536, while total levels of 
nuclear p65 are unchanged by DAPK depletion. Finally, we determined that NF-
κB p65 is required for the increase in NF-κB activity observed when DAPK is 
depleted from HCASMC, since depletion of p65 from the cells blocked the DAPK 
effect. 
 Our studies confirm that DAPK mRNA and protein is upregulated in mouse 
atherosclerotic lesions particularly in sm-α-actin expressing cells within the 
plaques. Additionally we demonstrate that DAPK expression is also upregulated 
in the carotid ligation injury model at 4-14 days post-ligation. This data together 
with the finding that DAPK has an inhibitory role in HCASMC migration and the 
known role of DAPK in cancer cell and fibroblast migration suggests that DAPK 
may be important for regulation of SMC migration in vivo, a critical element in the 
development of many vascular pathologies (54, 71). Several genes including 
MMP9 that are important for cellular migration and ECM formation were altered in 
response to depletion of DAPK from HCASMCs. The finding that depletion of 
DAPK enhances HCASMC migration, together with the central role of MMP9 in 
VSMC migration and the development of atherosclerosis led to further 
examination of the potential role of DAPK in regulating the expression of this 
molecule (26, 38, 62, 74, 87).  
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 Although the stability of MMP9 mRNA is unaffected by DAPK expression, 
total mRNA and protein levels are significantly altered, linking DAPK to 
transcriptional regulation of MMP9. Supporting this, MMP9 promoter activity was 
directly related to expression of DAPK. Several signaling pathways modulate 
expression of MMP9 including MAPK and NF-κB. Interestingly, while DAPK-
depletion had no effect on the activation of MAPK pathways in primary HCASMC, 
it did significantly alter NF-κB signaling. The finding that depletion of DAPK did 
not alter MAPK signaling was surprising, since DAPK had been previously shown 
to block the nuclear translocation of ERK, and to be required for JNK activation 
under at least some conditions (22, 32). Despite the fact that a statistically 
significant change in MMP9 expression was not observed when DAPK-depleted 
cells were treated with the MEK inhibitor U0126, there was a trend toward a 
decrease in MMP9 mRNA levels, suggesting that ERK activation may make a 
minor contribution to the increased MMP9 promoter activity observed in DAPK-
depleted cells. Relevant to this finding, a previous study utilizing aortic SMC 
demonstrated that ERK was required for maximal NF-κB activation and MMP9 
expression in response to TNFα (83), so it is possible that ERK may be acting 
upstream of NF-κB in HCASMC. 
  Previously, Chuang et al. linked DAPK to negative regulation of NF-κB 
signaling in T cells, and in this study DAPK was found to block nuclear 
translocation of p65 in response to T cell activation (27). Although our results did 
not show any alteration in nuclear translocation of p65, DAPK depletion resulted 
in a significant increase in nuclear p65 phosphoS536. This suggests that the 
mechanism utilized by DAPK to regulate T cell signaling is likely very different 
than that used in HCASMC. Consistent with this is the additional finding that the 
T cell signaling response requires an atypical protein kinase C isoform, PKC-θ. 
Another difference between these two cell types is the partial membrane-
association of DAPK in T cells, which clearly differs from our finding that DAPK is 
predominantly localized to the nucleus in HCASMC. This is another unanticipated 
finding, as it was previously reported that DAPK was predominantly found in the 
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cytoplasm, bound to actin filaments (28). Determining the localization of 
endogenous DAPK has been difficult in previous studies, as the available 
antibodies to DAPK are not suitable for immunofluorescent staining. Most, if not 
all, studies have relied on overexpression to visualize location of DAPK in the cell 
(7, 28). One previous study Cohen el al. suggested that DAPK localized with 
actin-containing insoluble fractions (28). It is possible that DAPK actually 
associates with DAPK with insoluble chromatin, which co-fractionated with actin 
in RIPA lysis buffer (28). Using a different cell fractionation protocol, we have 
found DAPK in the nucleus of several cell types, including HeLa and HEK293 
(data not shown), suggesting that the localization of DAPK to the nucleus is not 
necessarily cell type dependent. 
The increased level of nuclear p65 phosphoS536 when DAPK is depleted 
from HCASMC is an intriguing finding that can account for increased MMP9 
expression. This proposal is supported by the fact that no other alterations in NF-
κB family members were observed and because depletion of p65 resulted in 
blocking the DAPK effect on the MMP9 promoter. Thus, enhanced levels of 
nuclear p65 phosphoS536 is likely the reason for the observed increased NF-κB 
activity and MMP9 expression when DAPK is depleted from SMC. The NF-κB 
family member p65 can be phosphorylated on several different sites, and the 
roles of these phosphorylations are still being characterized (51). However, 
previous studies have determined that p65 phosphoS536 increases 
transactivation activity in luciferase assays (50), in agreement with our results in 
primary HCASMC. These previous studies have found that p65 phosphoS536 
can both dissociate repressors such as SMRT and HDAC3 from promoters, and 
recruit p300/CBP activators to promoters (24, 47). In addition, phosphorylation of 
serine 536 also may alter the localization of p65, as it reduces the ability of p65 to 
bind to IκBα, thus allowing p65 phosphoS536 to resist nuclear export (10, 13, 
39).  
 Several kinases are known to phosphorylate p65 on serine 536, including 
IκKα/β and RSK1 (102, 103). The finding that there is a significant increase in 
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p65 phosphoS536 when DAPK was depleted argues against the possibility that 
DAPK plays a direct role in phosphorylation of p65 at this site, even though it is a 
ser/thr kinase. In addition, examination of the p65 sequence did not reveal any 
sequences with similarity to other DAPK consensus phosphorylation site 
sequences (78, 106, 120). Since we observed an increase in p65 phosphoS536 
in DAPK-depleted cells, we hypothesized that DAPK was negatively regulating 
one of these kinases. However, we found no changes in the active, 
phosphorylated forms of IκKα/β in DAPK-depleted HCASMC, either in the basal 
state, or following TNFα-activation (Figure 10C). In addition, parthenolide, an 
inhibitor of IκKα/β, had no signficant effect on the increased levels of MMP9 
observed in DAPK-depleted cells (data not shown). These results led us to 
hypothesize about other mechanisms for regulating phosphorylation of p65, 
including phosphatase activity. One possibility is that PP2A, a known p65 
phosphatase (127) which was recently shown to physically interact with DAPK 
(123), is not effectively targeted to p65 in DAPK-depleted cells. This alternative 
suggests the existence of a complex of proteins including DAPK, PP2A and p65 
exists in cells; further studies will be required to validate this possibility. 
 Collectively, this report details a novel mechanism for regulation of VSMC 
migration that is modulated by the cellular levels of DAPK. DAPK appears to act 
upstream of NF-κB signaling and ultimately alters the level of p65 phosphoS536. 
Reduced DAPK expression enhances the levels of p65 phosphoS536 leading to 
increased MMP9 expression and increased VSMC migration. Current studies are 
focused on identifying the direct target of DAPK in the NF-κB signaling pathway 
and identifying additional transcriptional targets that are modulated by DAPK 
activity.   
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Figure 3: DAPK is upregulated in atherosclerosis and in response to 
vascular injury. 
A: Paraffin sections from the aortas of ApoE-/- and wild-type C57BL/6 mice (WT) 
that had been fed a Western diet for 3 months were stained to detect expression 
of DAPK or sm-α-actin. Brownish red staining represents areas of expression of 
DAPK or sm-α-actin. Histological staining with Masson’s Trichrome stain is also 
shown; red staining indicates cytoplasm and blue staining indicates collagen. B: 
qRT-PCR was performed on RNA isolated from nonplaque or plaque regions of 
aortas from ApoE-/- mice fed a Western diet for 2 months. RPLP0 was used as 
the endogenous control. The mRNA levels in plaque regions were normalized to 
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its own nonplaque control for each mouse aorta, and a paired t test was used to 
compare samples. * p<0.05; n=13 per group. C: Immunoblotting of RIPA lysates 
(20 µg/lane) from ligated carotid arteries was performed. Vinculin was used as a 
loading control. The graph shows quantitation of DAPK protein, normalized to 
vinculin. T tests were used to determine statistical significance, compared to 
uninjured arteries (0 d). ***p<0.001;  ** p<0.01; n=3. 
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Figure 4: DAPK negatively regulates HCASMC migration.  
A: Immunoblotting was performed on RIPA lysates from HCASMC that were 
serum-starved for 0-8 days to induce smooth muscle differentiation markers. 
Each lane represents 10 µg total protein, which was immunoblotted as indicated. 
DAPK levels were quantitated and normalized to GAPDH, as shown below blots. 
B & C: Modified Boyden chamber assays were performed using HCASMC that 
had been grown in serum-containing growth media. Upper well contained cells in 
serum-free medium, and lower well contained 10% FCS. Migrated cells were 
quantitated after 6 hours. Migrated cells in test samples normalized to control for 
each experiment. B: Two days before migration study, HCASMC were 
Nucleofected with either pcDNA3 or pcDNA3 DAPK construct. Results show 
mean +/- sem for three independent experiments. *P<0.05 by t test. C: Three 
days before migration study, HCASMC were Nucleofected with either control or 
DAPK siRNA. Results show mean +/- sem for five independent experiments. 
*P<0.05 by t test. D: Immunoblotting of lysates from parallel wells of HCASMC 
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used in migration studies showing overexpression of DAPK (left) and siRNA 
depletion of DAPK (right). Vinculin was used as a loading control. 
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Figure 5: DAPK negatively regulates MMP9 and VCAM1 expression.  
A: qRT-PCR was performed using cDNA from control or DAPK siRNA treated 
HCASMC with primers specific for MMP9. Growth media: cells were grown for 2 
days in growth media before RNA was collected. HPRT was used as the 
endogenous control. Results show mean +/- sem for three independent 
experiments. Serum-free media: cells were grown in growth media for 2 days, 
followed by serum-free media for 3 days. Results show mean +/- sem for three 
independent experiments. *p<0.05, **p<0.01. B: qRT-PCR was performed for 
VCAM1 as described in A, using serum-free media. Results show mean +/- sem 
for four independent experiments. ***p<0.001. C: Upper panels show 
immunoblots of RIPA lysates. Equal amounts of RIPA lysates from HCASMC 
were immunoblotted for DAPK and vinculin (loading control). Lower panels show 
immunoblot and gelatin zymography to measure relative MMP9 levels in 
conditioned media. Arrow denotes nonspecific band recognized by MMP9 
antibody. D: mRNA stability assay for MMP9. DAPK or control siRNA were 
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introduced into HCASMC by Nucleofection. After 3 days, the Nucleofected 
HCASMC in growth media were treated with either carrier (DMSO, 0.1%) or 
Actinomycin D (4 µM) for 8-24 hours. For serum-free media samples, HCASMC 
were serum-starved for 3 days prior to addition of DMSO or Actinomycin D. qRT-
PCR was performed on cDNAs generated, and MMP9 mRNA values were 
normalized to DMSO controls at each time point. The number of samples 
analyzed for each time point, n=3. 
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Figure 6: DAPK regulates MMP9 promoter activity by attenuating NF-kB 
activity. 
A: HCASMC were Nucleofected with control or DAPK siRNA. Two days after 
Nucleofection, serum-free media was added and cells were incubated for two 
days. Cells were treated with DMSO (0.1%), MEK1 inhibitor U0126 (5 µM), JNK 
inhibitor SP600125 (10 µM), or p38MAPK inhibitor SB203580 (5 µM) for 24 
hours, then RNA was collected, and cDNA generated. MMP9 mRNA was 
normalized to HPRT. Graph shows mean +/- sem for 4-6 independent 
experiments. **p<0.01. B: Upper panel shows sequence of wild-type and mutant 
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versions of plasmids used for MMP9 Luciferase constructs containing mutations 
in the NF-kB- and AP-1-binding sites of the human MMP9 promoter. HCASMC 
were Nucleofected with control or DAPK siRNA. After three days cells were 
Nucleofected a second time to introduce Luciferase constructs (2 µg pGL3b 
MMP9 or NFkB-Luc and 0.5 µg pTK Renilla). Cells were plated in triplicate in 
growth media. Each sample was normalized to Renilla to control for transfection 
variation, and DAPK siRNA normalized to control siRNA treated cells for each 
luciferase construct to calculate fold activation. Graph shows mean +/- sem for 3 
independent experiments. ***p<0.001, **p<0.01.  
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Figure 7: DAPK depletion does not alter p65 translocation to the nucleus. 
Primary HCASMC containing either control or DAPK siRNA were serum-starved 
for 18 hours. TNFα (10 ng/ml) was added as indicated for 15 minutes. Nuclear 
and cytosolic fractions were isolated, and equal amounts of protein were 
analyzed by immunoblotting as indicated. Vinculin and PARP are included as 
cystosolic and nuclear markers, respectively. The levels of nuclear p65 did not 
significantly vary between cells expressing DAPK and those depleted of DAPK. 
Immunoblots are representative of three independent experiments. 
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Figure 8: DAPK depletion increases p65 phosphoS536. 
A: Representative immunoblot of RIPA lysates from HCASMC after depletion of 
DAPK with siRNA. HCASMC were Nucleofected with control or DAPK siRNA. 
Cells were serum-starved for 3 days, and then stimulated with 10% FCS for 30 
minutes. RIPA lysates were collected and equal amounts of protein were 
immunoblotted as indicated. B: Quantification of p65 phosphoS536, normalized 
to total p65. Graph shows mean +/- sem for 6 independent experiments. *p<0.05 
by t test. 
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Figure 9:  Phosphorylation of p65 at S536 increases activation of NF-κB. 
A: HCASMC were Nucleofected with control or p65 siRNA. Three days later the 
cells were Nucleofected again with NF-κB-Luc (2 µg), pTK-Renilla (0.5 µg), and 
either pcDNA3, p65 WT, p65 S536A, or p65 S536D (2 µg) and cells were plated 
in growth medium. Luciferase assays were performed 18h after Nucleofection, 
measuring duplicate samples in triplicate wells. Fold NF-κB activation was 
determined by normalizing to control siRNA sample. Data is presented as mean 
+/- sem for triplicate wells a single experiment. *p<0.05 vs. pcDNA3/control 
siRNA (column 1); #p<0.05 vs. pcDNA3/p65 siRNA (column 2).  Similar results 
were obtained in three independent experiments. B: Immunoblotting of HCASMC 
lysates from p65 siRNA/p65 rescue experiment in parallel wells Nucleofected in 
A. C: Immunoblotting of HeLa lysates transfected with p65 constructs used in A 
and B. Vinculin is used as a loading control. 
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Figure 10: Increased MMP9 in DAPK-depleted HCASMC requires p65 
phosphoS536.  
A: HCASMC were Nucleofected with control or DAPK siRNA. Three days after 
Nucleofection, cells were serum-starved overnight. Cells were treated with or 
without TNFα (10 ng/ml) for 15 minutes to induce phosphorylation and nuclear 
translocation of p65. Cytosolic and nuclear fractions were prepared, and equal 
amounts were immunoblotted for p65 phosphoS536 and total p65. B: HCASMC 
were Nucleofected with siRNAs as indicated. Three days after Nucleofection, 
cells were Nucleofected again with NF-κB-Luc or wild-type MMP9 promoter 
construct and pTK-Renilla and the cells were plated in growth medium. After 
incubation for 18h, duplicate measurements were made for triplicate wells. The 
fold activation of promoter constructs was determined by normalizing to either 
control siRNA only, or to p65 siRNA only samples. *p<0.05 vs. control siRNA. C: 
Cells were treated as in A, except that RIPA lysates were prepared. 
Immunoblotting of TNFα (10 ng/ml) treated HCASMC revealed no difference in 
IκKα/β activation on S176/S180. 
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Table 1: Primers used for RTPCR 
 
Primer name  Sequence (5’ to 3’) 
Forward ATG GCT ATT ACT CCG TGG CTA AAG Mo DAPK Reverse TCA CAG CAA GAT GAA GAG CGA TG 
Forward GGA CCC GAG AAG ACC TCC TT Mo RPLP0 Reverse TGC TGC CGT TGT CAA ACA CC 
Forward GAA CCA ATC TCA CCG ACA GG Hu MMP9 Reverse GCC ACC CGA GTG TAA CCA TA 
Forward CCT TGG TCA GGC AGT ATA ATC CA Hu HPRT Reverse GGT CCT TTT CAC CAG CAA GCT 
Forward CAT GGA ATT CGA ACC CAA AC Hu VCAM1 Reverse TGT ATC TCT GGG GGC AAC AT 
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Chapter III: Generation and Characterization of a DAPK Knockout Mouse 
 
Introduction 
In the previous chapter, studies were described that addressed the role of 
DAPK in primary smooth muscle cells. This chapter outlines studies that address 
the role of DAPK in vivo. Much of the previous work regarding DAPK has been 
accomplished using cultured cell lines. A mouse model containing an in-frame 
deletion of part of the N-terminal kinase domain of DAPK has been generated 
and the resultant mouse expresses DAPK that lacks only a small region of the 
kinase domain (8, 63, 78). This animal is poorly characterized and its usefulness 
is limited by the fact that only a small region of the 160 kD DAPK protein is 
deleted to result in expression of nearly the entire molecule. Two other recent 
studies have been published which utilized two additional, independently 
generated DAPK knockout mouse models (42, 118). Gozuacik, et al. (2008) 
examined the effect of DAPK on ER stress in their DAPK knockout model, and 
found that DAPK is required for ER stress in kidney injected with thapsigargin. Tu 
et al. (2010) used a separate DAPK knockout mouse to examine the role of 
DAPK in a stroke model; they found that DAPK mediates neuronal death in 
response to stroke. Both of these models were generated using traditional, global 
gene knockout strategies. Up to this point, there have been no in vivo studies 
examining the effect of deletion of DAPK on vascular physiology and pathology. 
To accomplish this, a DAPK knockout (DAPK KO or DAPK-/-) mouse model was 
generated.  
Because of concerns that deletion of DAPK in all tissues could induce 
embryonic lethality, the choice was made to generate a conditional knockout 
mouse using the Cre-lox system. In addition, such a system offers many 
advantages over traditional knockout strategies, in that the control of deletion can 
be spatially and temporally regulated, depending on the Cre deleter mouse that is 
used. Thus, this chapter describes the first mouse containing a floxed DAPK 
gene. The generation and characterization of this mouse is outlined, together 
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with results from the carotid artery ligation injury model in which we sought to 
examine the effects of deletion of DAPK on the response to vascular injury in 
vivo. In this model, the right carotid artery is ligated, which prompts remodeling of 
the artery, increased MMP9 expression, and formation of a thickened medial 
smooth muscle layer and a neointimal layer in the lumen of the artery.  
 
Methods 
Generation of DAPKfl/fl mice. The BAC Engineering Core at the University of 
North Carolina generated the targeting vector shown in Figure 11. The BAC 
clone used in its construction (RPCI-105I10) was originally isolated from 
C57BL/6. After sequencing to confirm the location of the elements listed in 
Figure 11, the Indiana University Transgenic Mouse Core Facility generated ES 
clones resistant to neomycin by electroporating the construct into albino C57BL/6 
ES cells, and the resulting clones were grown and screened for homologous 
recombination of the floxed DAPK allele by PCR, Southern blotting, and 
sequencing of PCR-amplified floxed allele. ES clones were injected into C57BL/6 
blastocysts, and the resulting chimeras were mated to wild-type C57BL/6 to 
check for germline transmission. DAPKfl/+ heterozygotes were obtained and 
confirmed by PCR analysis, and crossed with each other to generate DAPKfl/fl   
homozygotes. The neo cassette was removed by mating the DAPKfl/fl female with 
a male mouse expressing the FLPe recombinase under control of the β-actin 
promoter (Actin-FLPe+/+; Jackson Laboratories). 
 
Generation of DAPK-/- mice. To generate DAPK-/- mice, male DAPKfl/fl mice 
were mated with smMHC-Cre+/- females. The smMHC-Cre+/- were obtained from 
Michael Kotlikoff (37, 125). Due to transient expression of Cre in these mice in 
eggs, this cross resulted in deletion of exon 4 in the floxed DAPK allele in the 
eggs, resulting in mice heterozygous for the DAPK allele in all tissues. The 
heterozygous smMHC-Cre+/- DAPK+/- females were then crossed with DAPKfl/fl 
males to generate DAPK knockout (DAPK KO or DAPK-/-) mice.  
  45 
 
Southern blotting. Genomic DNA was isolated from ES cell clones, and 2-5 µg  
was digested with BamHI. The digests were separated on a 0.8% agarose gel, 
the gel was incubated in 0.25 M HCl followed by 0.4 M NaOH, and DNA was 
transferred to positively charged nylon filter (Brightstar Plus, Ambion), in 0.4 M 
NaOH by downward capillary transfer. A 32P-labeled DNA probe was prepared 
using a agarose-gel purified, PCR-amplied fragment located 2140 nucleotides 
upstream of DAPK exon 4, following 32P-labeled using the NEBlot kit (New 
England Biolabs). After neutralization in 2x SSPE, the membrane was incubated 
in hybridization buffer (6x SSPE, 5x Denhardt’s solution, 0.5% SDS, and 100 
µg/ml salmon sperm DNA) at 65°C for 3 hours. The 32P-labeled probe was added 
and the blot was incubated at 65°C overnight with agitation. The membrane was 
washed and exposed to X-OMAT AR film (Kodak) with intensifying screens at -
80°C. Expected sizes are 5.8 kb for wild-type allele and 4.5 kb for the 
recombined, floxed allele. BAC clones were used as controls; unmodified clone 
RPCI-105I10 was a wild-type control, and a modified BAC clone containing the 
neo cassette and loxP sites surrounding DAPK exon 4 was used as a control for 
the floxed, recombined allele. Both BAC clones were supplied by the BAC 
Engineering Core (UNC). 
 
Genotyping. For screening of ES clones, genomic DNA was isolated from cells 
using the Gentra Puregene Cell Kit (Qiagen). For screening of mice, digits were 
cut from 12-14 day-old mouse pups. DNA was extracted by boiling the digits in 
125 ml 25 mM NaOH and 0.2 mM EDTA for 30 minutes, followed by addition of 
125 ml 40 mM Tris-HCl (117).  PCR amplification was done using GoTaq Green 
Master Mix (Promega), 0.5mM each primer, and DNA. PCR method was: 95°C 
for 2 minutes, followed by 35 cycles of 95°C for 30 seconds, 55°C for 30 
seconds, and 72°C for 1 minute. Amplicons were separated on a 1.4% agarose 
gel, and photographed using a Syngene GeneSnap. Primer sequences used for 
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genotyping are listed in Table 2. Sequencing of PCR amplicons to verify the 
distal loxP site was performed by Seqwright.  
 
Real-time RT-PCR. Mouse tissues were rinsed in PBS and then snap-frozen in 
liquid nitrogen. RNA was prepared from frozen mouse tissues by homogenizing 
the tissue in Trizol (Invitrogen), using increased amounts of glycogen (200 µg per 
artery) to precipitate the small amount of RNA obtained from individual carotid 
artery samples. Tests were performed to verify that the increased glycogen 
present in the RNA samples did not interfere with subsequent cDNA production, 
nor PCR amplification. 0.5 µg of RNA was reverse transcribed as previously 
described (131). cDNA was diluted 1:5 with water, then amplified using Faststart 
SYBR green master mix (Roche) and gene specific primers (Eurofins 
MWG/Operon) in a AB 7500 Real-Time System (Applied Biosystems). Relative 
abundance of mRNA was calculated using the 2-ΔΔCt method. HPRT was used as 
an internal control. Primer sequences used are listed in Table 3.  
 
Semi-quantitative RT-PCR. RNA and cDNA was prepared as described above. 
DAPK exon 4 and HPRT were amplified using gene-specific primers (see Table 
3). PCR was performed with the following cycling parameters: 95°C for 2’, 
followed by 95°C for 30 seconds, 57°C for 30 seconds, and 72°C for 30 seconds 
for 30 cycles (HPRT) or 35 cycles (DAPK). Amplified DNA was separated on a 
1.4% agarose gel, and photographed using a Syngene G-Box and GeneSnap 
software (Synoptics).  
 
Immunoblotting. Tissues were homogenized in RIPA lysis buffer containing 
protease inhibitor cocktail and phosphatase inhibitor cocktails 1and 2 (Sigma), 
using a glass tissue homogenizer. Protein was quantitated using BCA assay 
(Pierce). Equal amounts of proteins were separated by SDS-PAGE, and detected 
using standard immunoblotting protocols. Antibodies used were: MMP9 (a 
generous gift of Dr. Robert Senior (Washington University, St. Louis, MO) (5); 
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DAPK (from BD Biosciences); GAPDH (Novus); vinculin, α-sm-actin, and β-actin 
from Sigma. Immunoblots were imaged using a Syngene G-box and GeneSnap 
software (Synoptics). Quantitation of band intensity was performed using ImageJ 
(NIH). 
 
Gelatin zymography. Zymography was performed as previously described with 
a few revisions (73). Equivalent amounts of protein from RIPA lysates of tissues 
(20-50 µg) were separated by SDS-PAGE containing 7.5% acrylamide and 0.1% 
gelatin (Biorad). Gels were incubated in 2.5% Triton-X-100 for 30 minutes, then 
incubated in zymography buffer overnight at 37°C. (50 mM Tris pH 7.5, 200 mM 
NaCl, and 5 mM CaCl2). Gels were stained in 0.5% Coomassie Blue R-250 in 
7.5% methanol/7.5% acetic acid for 24 hours, followed by destaining in 7.5% 
methanol/7.5% acetic acid for 2 hours. Gels were dried and photographed using 
a Syngene G-box and GeneSnap software (Synoptics). 
 
Carotid artery injury model. Eight-week old DAPKfl/fl or DAPKfl/+ and DAPK-/- 
mice underwent the carotid ligation surgery as previously described with a few 
modifications (69). Briefly, mice were anesthetized with a cocktail of ketamine 
(0.1 mg/g) and xylazine (0.01 mg/g). The carotid artery was exposed via a 0.5-cm 
incision 1-mm from the midline on the mouse’s neck. A 4-0 silk suture was used 
to ligate the right common carotid artery, proximal to the bifurcation. For RNA and 
protein analysis, mice were sacrificed 1-14 days following injury, and the injured 
carotid artery rinsed in PBS and frozen in liquid nitrogen. Uninjured carotid 
arteries from mice that did not undergo surgery were used as controls. Lysates 
were prepared by grinding the frozen arteries in RIPA buffer containing protease 
and phosphatase inhibitors (Sigma) using a glass tissue homogenizer. For 
histological analysis, injured mice were anesthetized and then perfused, first with 
sterile saline (0.9%) containing 0.1 mM sodium nitroprusside and 1 mM 
adenosine, and then with RNAlater (Ambion). Arteries were fixed overnight in Z-
Fix (Anatech) and embedded in paraffin. Sections obtained 50 µm from the 
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suture were stained with Verhoeff-van Gieson elastin stain. Embedding, 
sectioning, and staining was performed by the Indiana University Anatomy and 
Cell Biology Histology Core. Images were obtained from a Nikon Eclipse 90i 
microscope, Nikon DS-Fil camera and Nikon Elements AR 3.0 software. Images 
were compiled in Adobe Photoshop. ImageJ was used to measure intima and 
neointimal areas in injured arteries. The intima was defined as the area between 
the inner and outer elastic lamina, and the neointima was defined as the area of 
cells and connective tissue (not blood cells) on the inside of the inner elastic 
lamina. At least two sections were measured for each artery and the average 
area was used in statistical analyses.  
 
Animal studies. All animal studies were approved by Indiana University IACUC. 
 
Data analysis. All experiments were independently performed at least three 
times. All statistical analysis and graphs were created using GraphPad Prism 
software (GraphPad Software, San Diego, CA). Graphs display mean +/- sem of 
at least three independent experiments. Statistical significance was determined 
by Student’s t test unless otherwise noted. 
 
Results 
 In order to determine the in vivo role that DAPK plays in mouse 
physiology, we sought to generate a DAPK knockout mouse. Previous data from 
this and other laboratories using cultured cell systems indicated a role for DAPK 
in regulating apoptosis and autophagy (8, 78). In light of this, and in order to 
allow the greatest flexibility in deleting DAPK from specific tissues, a DAPK 
flox/flox (DAPKfl/fl) mouse was generated, such that loxP sites flanked exon 4. 
These loxP sites can be acted upon by Cre recombinase to generate either a 
whole-body or a tissue specific deletion of DAPK. Figure 11 shows the targeting 
strategy used to generate the DAPKfl/fl mouse. Following Cre recombinase 
activity, exon 4 will be deleted. Deletion of exon 4 is expected to result in splicing 
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of exon 3 to exon 5 to generate a frame shift that incorporates a translational stop 
codon after 3 missense amino acid residues. The subsequent mRNA will encode 
a protein comprised of the first 95 amino acids together with 3 miscoded amino 
acids. This region of DAPK contains 81 residues of the kinase domain but will not 
be functional as all of the known conserved kinase domain motifs are deleted 
(44). The targeting construct encodes the gene for neomycin, which is used for 
positive selection, as well as a negative selection cassette encoding diptheria 
toxin. The targeting construct was linearized and electroporated into albino 
C57BL/6 ES cells (Stratagene), and resulting clones were screened by PCR. The 
PCR primers were positioned (Figure 12A, P1/P6) such that they would allow 
identification of correct targeting of the neo/flox cassette following electrophoresis 
of the PCR reaction products. Representative results are shown in Figure 12C; a 
1.2-kb band was detected in the amplified DNA from the DAPKfl/+ mice with 
primers P1/P6. In addition, Southern blotting was performed to verify clones with 
correct targeting of the neo/flox cassette following hybridization with an 
appropriate probe (Figure 12A). Figure 12B shows the result of the Southern 
blot experiments. As expected, the 32P-labeled probe hybridized with a 5.8-kb 
BamHI-fragment in DNA samples from negative control, non-electroporated ES 
cells, consistent with the expected results based on the sequence of the wild-type 
DAPK allele. A 5.8-kb wild-type band and a 4.5-kb band that corresponds to the 
size expected by the recombined allele hybridized to the labeled probe in DNA 
samples from heterozygous, DAPKfl/+ ES cells. BAC DNA was used as positive 
and negative controls for the Southern blot. Because of difficulties in finding 
unique restriction sites in the right targeting arm 3’ of exon 4, Southern blotting 
used to verify the correct placement of the distal loxP site between exon 4 and 5 
was inconclusive. To validate the correct placement of the distal loxP site, this 
region was amplified by PCR using primers P2 and P5, and then sequenced to 
verify the correct placement of both loxP sites. Two independent ES clones (#244 
and #315) containing correctly-targeted, floxed-exon 4 were injected into 
C57BL/6 blastocysts, and implanted into pseudopregnant females to generate 
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two independent DAPKfl/+ lines. The resulting chimeric pups were then mated with 
wild-type C57BL/6 mice, and the pups were screened by PCR with primers P2 
and P5, as is shown in Figure 12A and D.  
In order to delete the neomycin cassette, female DAPKfl/+ mice were mated 
with a male, C57BL/6 ACTFLPe mouse expressing the FLP recombinase under 
the control of the human ACTB promoter. This mating resulted in recombination 
between the FRT sites flanking the neomycin cassette and deletion (Δneo) of this 
cassette (Figure 11). The resulting DAPK flΔneo/+ mice (Figure 13A) were then 
backcrossed to each other to generate homozygous DAPKfloxΔneo/floxΔneo. The 
genotype of this strain was verified by PCR, using primers P1 and P4 as shown 
in Figure 13A. The PCR resulted in generating a single 0.7-kB fragment 
corresponding to a DAPKfloxΔneo/floxΔneomouse; DAPKfloxΔneo/+ mice generated both a 
0.7 kb fragment, and a 0.6kb wild-type fragment (Figure 13A). 
 To generate a full-body DAPK -/-  mouse, a DAPKfloxΔneo/floxΔneo  male was 
mated with a C57BL/6 smMHC-Cre+/- female. This smMHC-Cre mouse expresses 
Cre recombinase under control of the smMHC promoter. Due to a transient 
expression of Cre in the egg, in which the Cre protein is present in both Cre 
genetically positive and negative fertilized eggs, crossing a male 
DAPKfloxΔneo/floxΔneo with a female Cre+/- mouse results in all progeny having one 
DAPK allele deleted (DAPK+/-). Crossing the heterozygous DAPK+/- mice 
generated a full-body DAPK-/- line. The PCR results are shown in Figure 13B, 
confirming deletion of the DAPK exon 4 (primers P3 and P4, 0.35-kB fragment), 
and the presence of the recombined DE4 allele (primers P1 and P5, 0.72-kB 
fragment). 
 The deletion of DAPK exon 4 was confirmed by RT-PCR of RNA isolated 
from liver, using primers that spanned exons 3 and 4 to generate the expected 
0.2-kB fragment (Figure 14A). Primers to HPRT, which generated a 0.2-kB 
fragment, were used as a positive control to confirm the presence of RNA in all 
samples. In addition, the absence of DAPK protein was confirmed by 
immunoblotting lysates prepared from liver and brain tissues from DAPK+/+, 
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DAPK-/- , and DAPK+/- mice. These tissues were selected because they have high 
levels of DAPK expression. As is shown in Figure 14B, no DAPK protein was 
found in the liver or brain of DAPK-/- mice, and as expected reduced levels were 
observed in DAPK+/- mice.  
Examination of the DAPK-/- mice yielded no overt visible differences 
caused by the deletion of the DAPK protein. The DAPK-/- mice exhibited no 
changes in weight, when compared with wild-type counterparts from the same 
colony (Figure 15A). A reduction the sizes of litters from DAPK-/- mice was 
observed; Figure 15B shows that both DAPK-/- lines 244 and 315 exhibited 
reduced litter sizes, possibly indicating that there may be some reproductive 
problems or issues with the survival of some DAPK KO pups. The frequency of 
genotypes resulting from DAPK heterozygote crosses (DAPK+/- x DAPK+/-;from 
line 244), and from DAPK-/- and DAPK+/- (line 315) are shown in Table 4. For line 
244, there was a reduction in the expected percentage of DAPK-/- resulting from 
heterozygous parents (21% vs. the expected 25%); the reduction was more 
striking with males (13%). In addition, a reduction in the number of DAPK-/- was 
observed in line 315 (44% vs. the expected 50%). A Chi-squared analysis did not 
show that the difference is statistically significant and it is likely due to the small 
sample size for this study. It should be noted that this result agrees with a 
previous study that showed that male DAPK-/- mice were born at lower than 
expected frequencies (42). In the current study, two DAPKfl/fl and DAPK-/- lines 
were maintained (lines 244 and 315), and no differences have been observed 
between the lines. Data presented are from line 244, unless otherwise noted. 
 Data presented in Chapter II pointed to a role for DAPK in regulating 
MMP9 expression in vascular smooth muscle, with increased MMP9 mRNA and 
protein measured from HCASMC that had been depleted of DAPK using a DAPK 
siRNA. In order to determine if in vivo deletion of DAPK results in altered MMP9, 
immunoblotting and zymography was performed on RIPA lysates from mouse 
aorta obtained from DAPKfl/fl and DAPK-/- mice. Low levels of MMP9 protein were 
observed in the aorta; however they were not different between DAPKfl/fl and 
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DAPK-/- mice. (Figure 16A). The expression of MMP9 protein was lower in other 
tissues, such as carotid artery, liver and kidney, so qRT-PCR was used to detect 
changes in MMP9 mRNA. As is shown in Figure 16B, there was no change in 
the levels of MMP9 mRNA in carotid artery, liver or kidney tissues obtained from 
DAPK-/-, as compared with the same tissues obtained from DAPKfl/fl mice.  
 This result was surprising, especially in the aortic vascular tissue, as we 
had previously found that DAPK was a negative regulator of MMP9 in cultures of 
primary HCASMC (Chapter II, Figure 3). One possible explanation for this result 
is that in DAPK-/- mice a compensatory mechanism is engaged which blocks 
increased MMP9 expression. This possibility is not implausible, as increases in 
this protease are likely undesirable and incompatible with normal physiology. In 
support of this, macrophage specific transgenes overexpressing this protease 
have been described as having adverse effects on recruitment of neutrophils 
based on MMP9 activity inactivating certain chemokines (14, 119). However, 
compensation in whole animal knockouts is often not able to rescue the effects of 
the knockout under pathological conditions. In order to determine if DAPK has 
effects on MMP9 expression in an in vivo pathological condition, we examined 
the response of DAPK-/- mice to carotid artery ligation. This injury, which is 
schematically illustrated in Figure 17A, mimics blockage of arteries by thrombus 
formation, and results in the remodeling of the ligated artery (69). This 
remodeling is characterized by migration and subsequent proliferation of the 
medial smooth muscle cells in the lumen of the artery. Within 24h after ligation, a 
significant increase in MMP9 expression has been observed (40), indicating that 
this model would be appropriate to test the hypothesis that DAPK negatively 
regulates MMP9 in vivo. Figure 17B shows the results from western blotting of 
lysates prepared from the injured carotid arteries of a DAPK+/+ mouse. These 
results established the time course of expression of MMP9 and showed that in 
response to carotid ligation, the levels of MMP9 in the injured vessels increased 
from undetectable basal levels until 4 days post-injury, after which time the levels 
of MMP9 began to decrease and continued to do so until at least 14 days after 
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injury.  In addition, this experiment verified previous observations that expression 
of smooth muscle markers, such as smooth muscle α-actin (sm-α-actin) 
decreased over the first 7 days post-injury. This is likely due to de-differentiation 
of the vascular smooth muscle from contractile cells to more proliferative, 
migratory cells in response to the injury. In parallel, there was an increase in 
DAPK protein was observed as early as 4 days after injury, and maintained until 
at least 14 days post-injury (for quantification, see Chapter II, Figure 3C). Since 
both DAPKfl/fl and DAPKfl/+ were used as controls in this study the control mice will 
be denoted as DAPKfl.  Figure 18A and Figure 18B shows the results of western 
blots and gelatin zymograms of uninjured and injured carotid arteries at 1 and 7 
days post-injury. Quantification of these results revealed that there was a 9.6-fold 
increase in MMP9 levels within 1 day following injury in DAPKfl mice.   
 Based on the findings in cultured primary HCASMC (Chapter II), we 
expect DAPK to negatively regulate MMP9 expression. Thus, the DAPK-/- mice 
should exhibit an increase in MMP9 expression in injured carotid arteries, 
compared to DAPKfl mice. Unexpectedly, MMP9 levels at 7 days post-injury were 
actually lower in DAPK-/- mice compared to DAPKfl mice (Figure 18B). To 
quantify the levels of active MMP9 expressed in response to the ligation injury 
the intensity of MMP9 bands (Figure 18C) was quantitated and normalized to 
vinculin, which was used as a loading control. As is shown in Figure 18C there 
was no difference in expression of MMP9 observed at 1 day post-ligation, and 
although the effect at 7 days is not statistically significant, the trend indicates that 
DAPK-/- have lower levels of MMP9. To further verify these unexpected results, 
qRT-PCR was performed to measure MMP9 mRNA in injured and uninjured 
carotid arteries from control DAPKfl and DAPK-/- mice. As Figure 18D shows, 
ligation injury of the carotid artery resulted in a 12.5-fold increase in MMP9 
mRNA, and there was no difference between DAPKfl and DAPK-/- mice (12.5 +/- 
3.0 for DAPKfl vs. 14.1 +/- 2.3 for DAPK-/-). 
 Histological sections of carotid artery tissues were prepared from DAPKfl  
and DAPK-/- mice at 14 (Figure 19 A-D) and 28 days (Figure 19 E-H) post-
  54 
ligation injury. These sections were stained with Verhoeff-van Giesen stain to 
visualize morphological details of the tissues including the adventitial, medial and 
neointimal layers as well as the elastic laminae. Representative stained sections 
were examined at these two time points and this examination revealed an 
increase in the thickness of the medial smooth muscle in response to the carotid 
ligation injury (Figure 19). As can be seen by comparing panels A, B to C, D of 
Figure 19, DAPK-/- mice had reduced response to injury at 14 days. For 
comparison an uninjured control DAPKfl artery is shown in Figure 19-I 
Quantitation of the medial smooth muscle areas in these sections revealed that 
DAPK-/- mice had significantly smaller medial smooth muscle areas at 14 days 
after injury (Figure 19 A-D, and 19J). This trend was not observed at 28 days 
post-injury, however (Figure 19 E-H and 19J).  
DAPK has been previously implicated as a negative regulator of fibroblast 
and cancer cell migration(71). Results presented in Chapter II (Figure 2) 
indicated that DAPK also negatively regulates smooth muscle cell migation. 
Because the carotid ligation injury results in migration of smooth muscle cells into 
the lumen of the vessel to form a neointima, we hypothesized that the DAPK-/- 
mice would exhibit increased SMC migration in response to injury, resulting in an 
increased neointimal area at later time points post injury. The response to injury 
at 14 and 28 days post-injury in both the DAPKfl mice and DAPK-/- was quite 
varied; as is shown in Figure 19E-H, and many but not all mice showed 
development of a neointima at these time points. The ratio of neointimal to medial 
smooth muscle area is commonly used to compare the response to injury in 
vascular models. The quantitative results shown in Figure 19K reveal the 
heterogeneity in the response at 28 days, and suggest that there is no significant 
difference between the medial area or the neointimal/media ration for DAPKfl and 
DAPK-/- mice. Interestingly, on average, the DAPK-/- mice do show a trend toward 
having decreased neointimal formation at 14d post-injury (Figure 19K), with 
means of 0.203 +/- 0.08 in the DAPKfl/fl and 0.079 +/- 0.04 for the DAPK-/-.   
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Discussion 
 The data presented in this chapter are the results of studies following the 
generation of a DAPK knockout mouse. These studies show that we successfully 
generated a transgenic mouse containing loxP sites flanking exon 4 of DAPK. A 
heterozygous mouse was then generated by mating a male DAPKfl/fl mouse with 
a mouse that expresses Cre recombinase in eggs at the time of fertilization. 
Deletion of exon 4 was determined by PCR, RT-PCR, Southern, and 
immunoblotting. Analysis of mouse litter size indicated that the DAPK-/- mice 
produce significantly smaller litters than DAPK+/+ mice. In addition, when the 
numbers of DAPK-/- mice generated from heterozygous crosses were tabulated, 
there was a trend toward a decrease in the birth of DAPK-/- pups. Although the 
trend was not statistically significant due to the small sample size, it is likely that 
deletion of DAPK presents a challenge to the survival of mice during embryonic 
development.  
Based on the results from Chapter II showing that DAPK is a negative 
regulator of MMP9 in human coronary artery smooth muscle cells, it was 
hypothesized that deletion of DAPK would result in increased MMP9 expression. 
However, no changes were observed in MMP9 mRNA or protein levels in several 
tissues, including aorta, carotid artery, liver, and kidney, although future work 
should include more samples, to verify the results in liver and kidney, and to 
allow for statistical analysis of the data. Using the carotid artery ligation injury 
model, the effect of DAPK deletion on MMP9 levels in a pathological condition 
was tested. Both DAPK-/- and DAPKfl mice displayed a similar, robust increase in 
MMP9 protein and mRNA 1 day after injury. The MMP9 levels remained 
increased about basal up to 14 days following injury. Interestingly, in the DAPK-/- 
mice, there was a trend toward a reduction in the MMP9 protein observed 7d 
after injury, although future studies should first expand the sample size to allow 
statistical analysis of the quantification. In addition to inducing MMP9 expression, 
the carotid artery ligation also causes smooth muscle cell migration and 
proliferation to result in a thickened medial smooth muscle layer and the 
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generation of a neointimal cell layer that encroaches upon the lumen of the 
vessel. Examination of histological sections from DAPKfl  and DAPK-/- mice 
showed no significant difference in neointimal formation, however DAPK-/- mice 
generate significantly smaller medial smooth muscle layers 14 days following 
injury.  
The results in this study were surprising in many ways, but are 
instrumental in leading us to new areas in which to determine the in vivo role of 
DAPK. Based on the studies in Chapter II and previous studies, it was expected 
that DAPK-/- mice might have a myriad of problems which would be detrimental to 
their development. The strategy of using the Cre-lox system was decided upon 
because it was thought that deletion of DAPK in all tissues might induce 
embryonic lethality. During the generation of these mice, studies were published 
using adult mice from two independently-generated DAPK-/- mouse models (42, 
118). These studies indicated that our DAPK-/- mice would not likely be 
embryonic lethal. The DAPK-/- mice in our study exhibited normal growth, 
compared to the DAPKfl/fl mice that have normal levels of DAPK. Based on the 
results in Table 4, there was a trend toward reduced numbers of the DAPK-/- mice 
born, especially with male mice. This is in agreement with a previous study, 
which found slight decreases in numbers of male DAPK-/- mice, when compared 
to expected Mendelian ratios (42). This observation indicates that DAPK has an 
important role in promoting the development and survival of mice in utero. This 
also lends credence to the hypothesis that the surviving mice likely have 
alterations that allow them to compensate for the deleterious effects resulting 
from the loss of DAPK expression.  
We observed increased MMP9 expression in HCASMC when DAPK was 
depleted in studies reported in Chapter II. In cell culture, these effects did not 
adversely affect cell survival, but in an in vivo system such as the DAPK-/- mouse, 
such increases would likely alter development and might not be compatible with 
life. MMP9 is a protease that can digest extracellular matrix proteins and growth 
factors, altering their activity (86, 87). Expression of MMP9 is tightly regulated by 
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many cytokines, and the activity is tightly regulated in vivo by the expression of 
endogenous inhibitors such as TIMP-3 (87). Previous studies have linked 
alterations in the balance of TIMPs and MMPs with vascular pathology, like 
aneurysm (3, 35, 66). In addition, transgenic mice constitutively expressing 
MMP9 in macrophages exhibited less stable atherosclerotic plaques on an 
ApoE-/-  mouse background (41). An upregulation in MMP9 would likely be 
undesirable; thus the DAPK-/- mice that are born and survive likely have slight 
changes to reduce the expression. 
Another reason for the different results observed in Chapter II versus this 
chapter is that the studies in Chapter II were performed in human coronary artery 
smooth muscle cells, and in this in vivo study was performed on vascular tissue 
from aorta and carotid arteries. It is possible that the effect might be a species 
difference or a tissue origin difference, or that the signaling pathways activated in 
SMC culture differ from those activated in the response to carotid injury. The 
carotid injury model involves a more complex situation, with multiple cells 
contributing to MMP9 expression.  
Examination of the histological sections showed that DAPK-/- mice have 
smaller areas of medial smooth muscle. The decrease in MMP9 observed at 7d 
after injury could be contributing to the decreased medial smooth muscle area; 
however, more samples are needed to confirm the decrease in MMP9. 
Alternatively, the unexpected decrease in medial smooth muscle could be a 
direct effect of DAPK; previous work by this lab has found that primary aortic 
SMC require DAPK for survival (61). Perhaps the pathological conditions 
stimulated by the carotid injury result in apoptosis in SMC lacking DAPK.  
In conclusion, DAPK-/- mice have been generated which display defects in 
the response to carotid injury. The DAPK-/- mice exhibit reduced MMP9 
expression 7 days after injury. In addition, there is a decrease in medial smooth 
muscle area 14 days following injury. In Chapter IV, conclusions for these 
experiments are described and future studies are outlined to determine if there is 
a change in cell number, apoptosis, or proliferation. Studies will also seek to 
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identify the reason that DAPK has different effects on MMP9 expression in 
human CASMC and in the in vivo carotid injury model.  
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Figure 11: Strategy for generating DAPKfl and DAPK-/-.  
A targeting construct was generated containing loxP sites flanking exon 4 of the 
DAPK1 gene (red triangles). A neomycin resistance cassette (pGK Neo) flanked 
by FRT sites (yellow ovals) and a diptheria toxin A (DTA) gene (green box) were 
included in the targeting construct for use as a positive and negative selection of 
ES cell transgenes. Homologous recombination between the targeting vector and 
the gene results in generation of the floxed allele (+neo). Subsequent mating with 
the Actin-FLPe mouse (FLPe recombinase under the control of the human β-actin 
promoter) results in floxed allele (Δneo). Deletion of exon 4 is accomplished by 
mating the floxed allele (Δneo) mouse with a mouse expressing Cre recombinase 
to generate ΔE4 allele. This study used smMHC-Cre deleter mice, which contain 
Cre in the fertilized egg, generating a whole-body deletion of the DAPK Exon 4 
(ΔE4). 
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Figure 12: Verification of DAPK fl, DAPK flΔneo, and DAPK-/- mice.  
A: Location of the primers used for PCR verification of the floxed DAPK and 
DAPK KO mice (P1-P8). In addition, the Southern blot probe (SB probe) location 
is shown (red box).  B: Autoradiogram of a Southern blot showing the presence 
of the recombined, floxed DAPK allele (4.5-kb band) in two ES cell lysates, in 
addition to the wild-type DAPK allele (5.8 kb). BamHI was used to digest the 
genomic DNA, and the sites are indicated in panel A. Positive controls include 
BamHI digested BAC DNA (RPCI-105I10), which contains the section of the wild-
type (WT) DAPK1 gene shown in panel A. The targeting construct shown in 
Figure 11 was homologously recombined with the WT BAC to generate the “fl” 
positive control shown on the right. C - D are representative images of agarose 
gels used to identify PCR reaction products. The primers used and the size of the 
expected fragment, are indicated on to the left and right sides of the gels, 
respectively. C: PCR results from ES cells to validate the occurrence of 
homologous recombination between DAPK exon 3 and exon 4. P1/P6 generated 
a 1.2 kb product in ES cells where homologous recombination occurred; no band 
was observed where random integration of the construct occurred. D: PCR 
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fragments generated from genomic DNA samples of the indicated genotypes of 
flox mice. The sizes of the fragments verify the presence of the DAPKfl/+ and 
DAPKfl/fl alleles. P2/P5 primers amplify only the flox allele to generate a 2.0 kb 
fragment, P1/P4 primers will amplify only the WT allele to generated a 0.6 kb 
fragment and P3/P4 primers amplify within exon 4 to generate a 0.35 kb 
fragment.  
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Figure 13: Verification of DAPK flΔneo/flΔneo and DAPK -/- mice.  
A: PCR results from floxΔneo mice verify the presence of DAPKflΔneo/+ and 
DAPKflΔneo/flΔneo alleles. P1/P4 primers amplify a 0.7 kb region corresponding to the 
flΔneo allele, and a 0.6 kb region corresponding to the wild-type (wt) allele. B: 
PCR results to verify the alleles of the DAPK+/- and DAPK-/- mice. P3/P4 primers 
amplify exon 4 to generate 0.35 kb amplicons for wild-type or the floxed allele but 
do not amplify the deleted exon 4 (ΔExon 4). P1/P5 primers generate a 0.72 kb 
amplicon for the ΔExon 4 allele. 
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Figure 14: Verification of deletion of DAPK mRNA and protein. 
A: Semi-quantitative RT-PCR was performed on liver RNA obtained from 
DAPK+/+, DAPK +/-, and DAPK-/- mice. DAPK-/- mice showed no amplification of the 
DAPK exons 3/4 (upper, lane 1) and DAPK+/- showed reduced levels when 
compared to DAPK+/+. Primers to HPRT were used as an internal control. A no-
template (nt) control was also tested. B: Immunoblotting verified the absence of 
DAPK protein in lysates from the  liver and brain of DAPK KO mice, and reduced 
levels in lysates from DAPK+/-. Anti-DAPK monoclonal antibody (Sigma) was 
used to detect expression of DAPK in 80 µg liver and 70 µg of brain cell extracts. 
Vinculin and β-actin were used as loading controls. 
  64 
 
Figure 15: Statistical analysis of growth and litter size in WT and DAPK KO 
mice. 
A: Weights of mice were tabulated at various times and graphed as indicated. 
WT litters were used for comparison because there were not enough DAPKfl/fl 
litters at time of publication. B: Mouse litter sizes for two lines of DAPKfl/fl or 
DAPK-/- mice were tabulated and graphed as indicated. For the combined 
column, data from the 244 and 315 lines were combined. ** p<0.01, *** p<0.001. 
DAPK KO denotes DAPK-/- genotype. Sample sizes were: 244 DAPKfl/fl (n=34), 
244 DAPK KO (n=29), 315 DAPKfl/fl (n=25), 315 DAPK KO (n=21), combined 
DAPKfl/fl (n=59), and combined DAPK KO (n=50).  
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Figure 16: Quantitation of MMP9 protein and mRNA in DAPK-/- mice. 
A: RIPA lysates from DAPKfl/fl and DAPK-/- (denoted DAPK KO) mice were 
analyzed by immunoblotting for DAPK (Sigma) and MMP9, and gelatin 
zymography.  Each lane on the gel represents 50 µg total protein. B: qRT-PCR 
was performed on cDNA generated from total RNA prepared from carotid artery, 
liver, and kidney of control DAPKfl/fl and DAPK KO (DAPK-/-) mice as indicated. 
MMP9 mRNA was normalized to HPRT. Values were then normalized to the 
average of the DAPKfl/fl group for comparison. N=6 for carotid artery, n=2 for liver 
and kidney. 
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Figure 17: Expression of MMP9 is upregulated by carotid ligation. 
A: Schematic showing the region of the right carotid artery ligated; the region 
highlighted by the box was collected for protein and mRNA analysis. B: Lysates 
from carotid arteries of WT C57BL/6 0-14 days post injury were analyzed as 
indicated. Immunoblotting results from mice showing the response to injury at the 
protein level from 0-14 days after injury. DAPK antibody was from BD. Carotid 
arteries from uninjured mice were used as negative controls. RIPA lysates (20 µg 
per lane) were blotted for the indicated proteins.   
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Figure 18: MMP9 is upregulated in both DAPKfl and DAPK -/- mice; MMP9 
mRNA is decreased in DAPK-/- mice at 7d after injury.  
A-B: Lysates from carotid arteries of WT C57BL/6 1 and 7 days post injury were 
analyzed as indicated. Immunoblotting results from mice showing the response to 
injury at the protein level from 0-14 days after injury. Carotid arteries from 
uninjured mice were used as negative controls. RIPA lysates (20 µg per lane) 
were blotted for the indicated proteins.  Immunoblotting and zymography results 
1 day (A) and 7 days (B) post-injury from DAPK fl and DAPK-/- mice (denoted 
DAPK KO). DAPK monoclonal antibody was from BD. C: MMP9 was quantitated 
on zymograms in A & B, and normalized to the immunoblotted vinculin. N values 
are as indicated. D: qRT-PCR was used to measure MMP9 mRNA in RNA 
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samples obtained from DAPK fl/ or DAPK KO mice at 1 day post-injury. Levels 
were normalized to mouse HPRT. N=6. 
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Figure 19: DAPK -/- mice exhibit less medial response to carotid injury after 
14d. 
A-H: Representative paraffin sections of injured arteries from DAPKfl and DAPK-/- 
mice after fixation and staining with Verhoeff-Van Gieson which stains the elastic 
laminae black. A, B, C, D: 14 days after injury; E, F, G, H: 28 days after injury.    
I: Uninjured control artery. A, B, E, F are arteries from DAPKfl mice; C, D, G, H 
are arteries from DAPK -/- mice (denoted DAPK KO). Scale bar in panel A shows 
100 µm. J – K: Using ImageJ software, area of the medial smooth muscle layers 
  70 
or the ratio of neointimal area (area of non-blood cell growth in lumen inside of 
inner elastic lamina) to the media area was measured, calculated, and graphed. 
Medial smooth muscle was defined as the area between the inner and outer 
elastic lamina. The numbers of arteries examined were: n=12 for 14 days DAPKfl 
and DAPK KO; n=10 for 28d DAPK fl and n=9 for 28d DAPK KO. Duplicate 
sections were measured for each mouse. *p=0.034, DAPKfl vs. DAPK KO, 14d 
post-injury. 
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Table 2: Primers used for RT-PCR 
 
Primer name  Sequence (5’ to 3’) 
Forward TCATTCTGATCCTGGAGCTTG Mo DAPK (exon 4)  Reverse TGCCTCCTCTTCAGTCAGAGA 
Forward TGGCCCTCTGTGTGCTCAA Mo HPRT Reverse TGATCATTACAGTAGCTCTTCAGTCTGA 
Forward CCTGAAAACCTCCAACCTCA Mo MMP9 Reverse GGTGTAACCATAGCGGTACAAGT 
 
 
Table 3: Primers used for genotyping and Southern blot probe template 
 
Primer name Sequence (5’ to 3’) 
P1 TGCTTACTGTCTGGCAGTGG 
P2 GCTTCCTCGTGCTTTACGGTATC 
P3 TCTGTCCCCTCGTTTGTGAATG 
P4 CAGGTGCCTCAGTTTCTCTTGG 
P5 ATAGGAGCACAGCCCGTCTTGACAG 
P6 TGGACGTAAACTCCTCTTCAGACCTG 
P7 GCATTGAGCACCTTCCTTCACAC 
P8 CGGAGCATTTCAGATGGCACTG 
Southern probe forward GAAGGAAGGGTTGAGAGAGTTGC 
Southern probe reverse CCAAGTTTGAGACAAGGCAGAGTC 
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Table 4: Frequency of genotypes observed 
 
Line 244 
244 (+/- x +/-) DAPK +/+ DAPK+/- DAPK -/- 
Males 12 (27%) 27 (60%) 6 (13%) 
Females 9 (22.5%) 19 (47.5%) 12 (30%) 
Combined 21 (25%) 46 (54%) 18 (21%) 
    
    
P value combined 0.67   
P value males 0.18   
P value females 0.76   
 
 
Line 315 
315 (+/- x -/-) DAPK +/- DAPK -/- 
Males 17 (57%) 13 (43%) 
Females 15 (56%) 12 (44%) 
Combined 32 (56%) 25 (44%) 
   
   
P value combined 0.35  
P value males 0.47  
P value females 0.67  
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Chapter IV: Future Studies and Conclusions 
  
The results presented in the previous two chapters point to a role for 
DAPK in regulation of smooth muscle signaling. Chapter II focused on the 
regulation of MMP9 expression by modulating p65 activity in primary human 
coronary smooth muscle cells, and Chapter III presented studies using a newly 
generated DAPK-/- mouse. Examination of this mouse model revealed that DAPK 
promotes MMP9 expression and development of thickened media in a carotid 
injury model. Future studies will be delineated in this chapter to advance our 
understanding of the role of DAPK has on the physiology and pathology of 
smooth muscle and other tissues. 
 In Chapter II, results showed that DAPK negatively regulates levels of p65 
phosphoS536. Using a phosphomimetic mutant p65 S536D, we showed that this 
phosphorylated form of p65 increases the NF-κB activity, and that the inhibitory 
effect of DAPK requires p65 to modulate MMP9 expression levels. Further 
studies are needed to confirm that DAPK depletion leads to increased binding of 
p65 phosphoS536 on the MMP9 and VCAM1 promoters. Chromatin 
immunoprecipitation assays should be used to examine the binding of p65 to 
endogenous promoters in control and DAPK-depleted HCASMC; increased 
binding of p65 phosphoS536 to the MMP9 and VCAM1 promoters is expected 
when DAPK is depleted from HCASMC. Other NF-κB regulated promoters that 
are not responsive to DAPK depletion (IL-8 and TNFα, data not shown) should 
be used as negative controls. In addition, the role of p65 partner NF-κB1/p50 in 
the transcription of MMP9 and VCAM1 should be explored to determine if its 
binding is also affected by DAPK depletion. 
 DAPK depletion results in increased p65 phosphoS536 via an unknown 
mechanism. There are several kinases that can phosphorylate p65 at S536, 
including IκKα/β and RSK. There was no increase in the active forms of IκKα/β in 
DAPK-depleted HCASMC, leading to the hypothesis that perhaps 
dephosphorylation of p65 was affected in these cells. PP2A has been previously 
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shown to both bind DAPK and also to dephosphorylate p65 phosphoS536. This 
ser/thr phosphatase is also partially localized to the nucleus in HCASMC (data 
not shown). Thus, it is possible that DAPK and PP2A are part of a complex that 
regulates the phosphorylation status of nuclear p65. Future studies should focus 
on determining if DAPK, PP2A and p65 form a complex, and if DAPK depletion 
leads to disruption of the PP2A/p65 complex. Alternatively, another binding 
partner of DAPK might be mediating the effect on p65. DAPK has also been 
shown to bind to Mib1, an E3 ubiquitin ligase. Previous studies have shown that 
p65 phosphoS536 is specifically targeted for degradation by the nuclear 
proteasome (72). Depletion of DAPK could disrupt the ubiquitination of p65 by 
Mib1; future studies should focus on determining if Mib1 can ubiquitinate p65 in 
vitro and in vivo, and whether or not Mib1 and p65 interact. The levels of p65 
phosphoS536 phosphorylation and turnover are likely to be tightly regulated 
because p65 phosphoS536 does not bind IkBα (10, 13). This inhibitor of NF-κB 
signaling is responsible for maintaining p65 in the cytoplasm; thus, alternative 
mechanisms for terminating and regulating NF-κB signaling on promoters that 
bind p65 phosphoS536 are likely important and not well defined. Identification of 
the specific effect that DAPK has upon regulation of p65 phosphoS536 will 
further the knowledge in this field. 
  Another finding in Chapter II was that DAPK is localized to the nucleus. 
This finding was based on cell fractionation of HCASMC, and has been also 
found to be true for other cell line such as HeLa and 293HEK. Further studies to 
determine the regulation of DAPK nuclear localization are needed, such as 
characterization of sequences in DAPK that regulate its nuclear localization. One 
such highly basic amino acid sequence is located within the kinase domain of 
DAPK and site directed mutagenesis could be used to alter these residues and 
determine if nuclear localization was blocked. 
Chapter III showed that the deletion of DAPK in vivo has a different effect 
on MMP9 than was shown in Chapter II. In normal aortic, carotid artery, or 
hepatic tissue from DAPKfl/fl and DAPK-/- mice, there was no difference in MMP9 
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mRNA or protein expression. Reduced levels of MMP9 were found at 7 days 
following ligation of the carotid artery in the small sample size examined. The 
sample size in this study should be expanded, and also data for MMP9 mRNA 
levels determined for the 7 day post-injury time point. After verification of the 
decreased MMP9 at 7 days in the DAPK KO mice, the reasons for the different 
effect that low DAPK levels have on MMP9 expression should be explored. The 
carotid artery is a complex environment, and more than one cell type likely 
contributes to the MMP9 levels produced in response to vascular injury, including 
SMC and macrophages. Further studies need to be done to determine which 
cells are primarily responsible for the production of MMP9 mRNA in the carotid 
artery ligation. It is also possible that the differences we observe are due to 
unique properties of coronary artery smooth muscle cells, as compared to aortic 
and carotid artery smooth muscle cells. Examination of mouse coronary arteries 
is difficult, so future studies should first focus on characterizing the role of DAPK 
in primary carotid smooth muscle cells from mouse and human tissue, and also 
in macrophages and immune cells. Depletion of DAPK in these other cell culture 
models should be done to determine what effect DAPK has on MMP9 
expression. In addition, compensatory mechanisms are likely to be playing a role 
in masking the effects of the DAPK deletion and could explain the differences 
between acute depletion in cultured HCASMC compared to total sustained 
depletion in the mouse model. Further studies should examine if there are 
alterations in the NF-κB pathway to block the increased p65 phosphoS536 that 
may occur in the absence of DAPK. 
Data presented in Chapter III indicates that DAPK-/- mice have decreased 
medial smooth muscle thickness at 14 days post injury. More studies should 
determine if these differences are due to changes in cell number, apoptosis, and 
proliferation. In Chapter II, staining of sections from ApoE-/- mice showed that 
DAPK expression is upregulated in atherosclerotic lesions from ApoE-/- mice that 
have been fed a high-fat diet. Double-knockout mice (DAPK-/-; ApoE-/-) should be 
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generated to determine if the increased DAPK contributes to the generation of 
atheromas.  
The DAPK-/- mice were generated from a mouse that contained loxP sites 
around DAPK exon 4. These mice can be used in the future to generate tissue 
specific knockout mice in an unlimited number of studies to determine the effect 
of DAPK on specific cell types, such as endothelial cells, smooth muscle cells, 
immune cells, and other cell types, in both normal and injured arteries. Studies in 
nonvascular, DAPK-expressing tissues could also be undertaken using other Cre 
deleter mice. Because the deletion of DAPK is likely inducing compensatory 
changes to ensure the animals’ survival, use of an inducible Cre system would 
allow for temporal control of DAPK deletion after the animals reach maturity. This 
strategy could reveal more effects of the loss of DAPK.   
In conclusion, results presented here highlight roles for DAPK in vascular 
smooth muscle, both in human coronary artery smooth muscle cells and in vivo in 
the mouse carotid artery ligation model. DAPK levels were increased in the 
smooth muscle cells in two mouse models of vascular pathology. In the 
HCASMC, reduced DAPK levels led to increased cell migration and MMP9 
expression. The mechanism behind the in vitro upregulation of MMP9 was 
identified, and we found that reduced DAPK leads to increased phosphorylated 
p65, which has more NF-κB activity on the MMP9 promoter. DAPK also plays a 
role in vascular pathology in vivo; in the DAPK-/- mice there was a reduced medial 
response to ligation of the carotid artery, and also less MMP9 expression. Thus, 
depending on the context and possibly cell type, DAPK plays different roles in 
regulation of cellular signaling that determines the amount of MMP9 produced by 
cells. In conclusion, DAPK plays a complex role in the regulation of vascular 
smooth muscle signaling. 
  77 
References 
 
1. Allayee, H., A. Ghazalpour, and A. J. Lusis. 2003. Using mice to dissect 
genetic factors in atherosclerosis. Arterioscler Thromb Vasc Biol 23:1501-
9. 
2. Anjum, R., P. P. Roux, B. A. Ballif, S. P. Gygi, and J. Blenis. 2005. The 
tumor suppressor DAP kinase is a target of RSK-mediated survival 
signaling. Curr Biol 15:1762-7. 
3. Annabi, B., D. Shedid, P. Ghosn, R. L. Kenigsberg, R. R. Desrosiers, M. 
W. Bojanowski, E. Beaulieu, E. Nassif, R. Moumdjian, and R. Beliveau. 
2002. Differential regulation of matrix metalloproteinase activities in 
abdominal aortic aneurysms. J Vasc Surg 35:539-46. 
4. Barrett, T. B., and E. P. Benditt. 1988. Platelet-derived growth factor gene 
expression in human atherosclerotic plaques and normal artery wall. Proc 
Natl Acad Sci U S A 85:2810-4. 
5. Betsuyaku, T., Y. Fukuda, W. C. Parks, J. M. Shipley, and R. M. Senior. 
2000. Gelatinase B is required for alveolar bronchiolization after 
intratracheal bleomycin. Am J Pathol 157:525-35. 
6. Bialik, S., H. Berissi, and A. Kimchi. 2008. A high throughput proteomics 
screen identifies novel substrates of death-associated protein kinase. Mol 
Cell Proteomics 7:1089-98. 
7. Bialik, S., A. R. Bresnick, and A. Kimchi. 2004. DAP-kinase-mediated 
morphological changes are localization dependent and involve myosin-II 
phosphorylation. Cell Death Differ 11:631-44. 
8. Bialik, S., and A. Kimchi. 2010. Lethal weapons: DAP-kinase, autophagy 
and cell death: DAP-kinase regulates autophagy. Curr Opin Cell Biol 
22:199-205. 
9. Bialik, S., and A. Kimchi. 2006. The death-associated protein kinases: 
structure, function, and beyond. Annu Rev Biochem 75:189-210. 
10. Bohuslav, J., L. F. Chen, H. Kwon, Y. Mu, and W. C. Greene. 2004. p53 
induces NF-kappaB activation by an IkappaB kinase-independent 
mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J 
Biol Chem 279:26115-25. 
11. Bottger, B. A., U. Hedin, S. Johansson, and J. Thyberg. 1989. Integrin-
type fibronectin receptors of rat arterial smooth muscle cells: isolation, 
partial characterization and role in cytoskeletal organization and control of 
differentiated properties. Differentiation 41:158-67. 
12. Braun, M., P. Pietsch, K. Schror, G. Baumann, and S. B. Felix. 1999. 
Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc 
Res 41:395-401. 
  78 
13. Buss, H., A. Dorrie, M. L. Schmitz, E. Hoffmann, K. Resch, and M. Kracht. 
2004. Constitutive and interleukin-1-inducible phosphorylation of p65 NF-
{kappa}B at serine 536 is mediated by multiple protein kinases including 
I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family 
member-associated (TANK)-binding kinase 1 (TBK1), and an unknown 
kinase and couples p65 to TATA-binding protein-associated factor II31-
mediated interleukin-8 transcription. J Biol Chem 279:55633-43. 
14. Cabrera, S., M. Gaxiola, J. L. Arreola, R. Ramirez, P. Jara, J. D'Armiento, 
T. Richards, M. Selman, and A. Pardo. 2007. Overexpression of MMP9 in 
macrophages attenuates pulmonary fibrosis induced by bleomycin. Int J 
Biochem Cell Biol 39:2324-38. 
15. Cai, Q., L. Lanting, and R. Natarajan. 2004. Growth factors induce 
monocyte binding to vascular smooth muscle cells: implications for 
monocyte retention in atherosclerosis. Am J Physiol Cell Physiol 
287:C707-14. 
16. Cai, Q., L. Lanting, and R. Natarajan. 2004. Interaction of monocytes with 
vascular smooth muscle cells regulates monocyte survival and 
differentiation through distinct pathways. Arterioscler Thromb Vasc Biol 
24:2263-70. 
17. Camejo, G., G. Fager, B. Rosengren, E. Hurt-Camejo, and G. Bondjers. 
1993. Binding of low density lipoproteins by proteoglycans synthesized by 
proliferating and quiescent human arterial smooth muscle cells. J Biol 
Chem 268:14131-7. 
18. Campbell, J. H., and G. R. Campbell. 1994. The role of smooth muscle 
cells in atherosclerosis. Curr Opin Lipidol 5:323-30. 
19. Chait, A., and T. N. Wight. 2000. Interaction of native and modified low-
density lipoproteins with extracellular matrix. Curr Opin Lipidol 11:457-63. 
20. Chandrasekar, B., S. Mummidi, L. Mahimainathan, D. N. Patel, S. R. 
Bailey, S. Z. Imam, W. C. Greene, and A. J. Valente. 2006. Interleukin-18-
induced human coronary artery smooth muscle cell migration is dependent 
on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression 
and is inhibited by atorvastatin. J Biol Chem 281:15099-109. 
21. Chang, M. Y., S. Potter-Perigo, C. Tsoi, A. Chait, and T. N. Wight. 2000. 
Oxidized low density lipoproteins regulate synthesis of monkey aortic 
smooth muscle cell proteoglycans that have enhanced native low density 
lipoprotein binding properties. J Biol Chem 275:4766-73. 
22. Chen, C. H., W. J. Wang, J. C. Kuo, H. C. Tsai, J. R. Lin, Z. F. Chang, and 
R. H. Chen. 2005. Bidirectional signals transduced by DAPK-ERK 
interaction promote the apoptotic effect of DAPK. EMBO J 24:294-304. 
23. Chen, L. F., and W. C. Greene. 2004. Shaping the nuclear action of NF-
kappaB. Nat Rev Mol Cell Biol 5:392-401. 
24. Chen, L. F., S. A. Williams, Y. Mu, H. Nakano, J. M. Duerr, L. Buckbinder, 
and W. C. Greene. 2005. NF-kappaB RelA phosphorylation regulates 
RelA acetylation. Mol Cell Biol 25:7966-75. 
  79 
25. Cho, A., J. Graves, and M. A. Reidy. 2000. Mitogen-activated protein 
kinases mediate matrix metalloproteinase-9 expression in vascular 
smooth muscle cells. Arterioscler Thromb Vasc Biol 20:2527-32. 
26. Cho, A., and M. A. Reidy. 2002. Matrix metalloproteinase-9 is necessary 
for the regulation of smooth muscle cell replication and migration after 
arterial injury. Circ Res 91:845-51. 
27. Chuang, Y. T., L. W. Fang, M. H. Lin-Feng, R. H. Chen, and M. Z. Lai. 
2008. The tumor suppressor death-associated protein kinase targets to 
TCR-stimulated NF-kappa B activation. J Immunol 180:3238-49. 
28. Cohen, O., E. Feinstein, and A. Kimchi. 1997. DAP-kinase is a 
Ca2+/calmodulin-dependent, cytoskeletal-associated protein kinase, with 
cell death-inducing functions that depend on its catalytic activity. EMBO J 
16:998-1008. 
29. Corjay, M. H., M. M. Thompson, K. R. Lynch, and G. K. Owens. 1989. 
Differential effect of platelet-derived growth factor- versus serum-induced 
growth on smooth muscle alpha-actin and nonmuscle beta-actin mRNA 
expression in cultured rat aortic smooth muscle cells. J Biol Chem 
264:10501-6. 
30. Deiss, L. P., E. Feinstein, H. Berissi, O. Cohen, and A. Kimchi. 1995. 
Identification of a novel serine/threonine kinase and a novel 15-kD protein 
as potential mediators of the gamma interferon-induced cell death. Genes 
Dev 9:15-30. 
31. Doran, A. C., N. Meller, and C. A. McNamara. 2008. Role of smooth 
muscle cells in the initiation and early progression of atherosclerosis. 
Arterioscler Thromb Vasc Biol 28:812-9. 
32. Eisenberg-Lerner, A., and A. Kimchi. 2007. DAP kinase regulates JNK 
signaling by binding and activating protein kinase D under oxidative stress. 
Cell Death Differ. 
33. Endres, M., U. Laufs, H. Merz, and M. Kaps. 1997. Focal expression of 
intercellular adhesion molecule-1 in the human carotid bifurcation. Stroke 
28:77-82. 
34. Falk, E. 2006. Pathogenesis of atherosclerosis. J Am Coll Cardiol 47:C7-
12. 
35. Fitzgerald, M., I. P. Hayward, A. C. Thomas, G. R. Campbell, and J. H. 
Campbell. 1999. Matrix metalloproteinase can facilitate the heparanase-
induced promotion of phenotype change in vascular smooth muscle cells. 
Atherosclerosis 145:97-106. 
36. Fraser, J. A., and T. R. Hupp. 2007. Chemical genetics approach to 
identify peptide ligands that selectively stimulate DAPK-1 kinase activity. 
Biochemistry 46:2655-73. 
37. Frutkin, A. D., H. Shi, G. Otsuka, and D. A. Dichek. 2007. Targeted 
rearrangement of floxed alleles in smooth muscle cells in vivo. Circ Res 
101:e124-5. 
  80 
38. Galis, Z. S., C. Johnson, D. Godin, R. Magid, J. M. Shipley, R. M. Senior, 
and E. Ivan. 2002. Targeted disruption of the matrix metalloproteinase-9 
gene impairs smooth muscle cell migration and geometrical arterial 
remodeling. Circ Res 91:852-9. 
39. Ghosh, C. C., S. Ramaswami, A. Juvekar, H. Y. Vu, L. Galdieri, D. 
Davidson, and I. Vancurova. 2010. Gene-specific repression of 
proinflammatory cytokines in stimulated human macrophages by nuclear 
IkappaBalpha. J Immunol 185:3685-93. 
40. Godin, D., E. Ivan, C. Johnson, R. Magid, and Z. S. Galis. 2000. 
Remodeling of carotid artery is associated with increased expression of 
matrix metalloproteinases in mouse blood flow cessation model. 
Circulation 102:2861-6. 
41. Gough, P. J., I. G. Gomez, P. T. Wille, and E. W. Raines. 2006. 
Macrophage expression of active MMP-9 induces acute plaque disruption 
in apoE-deficient mice. J Clin Invest 116:59-69. 
42. Gozuacik, D., S. Bialik, T. Raveh, G. Mitou, G. Shohat, H. Sabanay, N. 
Mizushima, T. Yoshimori, and A. Kimchi. 2008. DAP-kinase is a mediator 
of endoplasmic reticulum stress-induced caspase activation and 
autophagic cell death. Cell Death Differ 15:1875-86. 
43. Gupta, S., A. M. Pablo, X. Jiang, N. Wang, A. R. Tall, and C. Schindler. 
1997. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J 
Clin Invest 99:2752-61. 
44. Hanks, S. K., and T. Hunter. 1995. Protein kinases 6. The eukaryotic 
protein kinase superfamily: kinase (catalytic) domain structure and 
classification. FASEB J 9:576-96. 
45. Hautmann, M. B., C. S. Madsen, and G. K. Owens. 1997. A transforming 
growth factor beta (TGFbeta) control element drives TGFbeta-induced 
stimulation of smooth muscle alpha-actin gene expression in concert with 
two CArG elements. J Biol Chem 272:10948-56. 
46. Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-kappaB 
signaling. Cell 132:344-62. 
47. Hoberg, J. E., A. E. Popko, C. S. Ramsey, and M. W. Mayo. 2006. 
IkappaB kinase alpha-mediated derepression of SMRT potentiates 
acetylation of RelA/p65 by p300. Mol Cell Biol 26:457-71. 
48. Houle, F., A. Poirier, J. Dumaresq, and J. Huot. 2007. DAP kinase 
mediates the phosphorylation of tropomyosin-1 downstream of the ERK 
pathway, which regulates the formation of stress fibers in response to 
oxidative stress. J Cell Sci 120:3666-77. 
49. Hu, J., M. Haseebuddin, M. Young, and N. H. Colburn. 2005. Suppression 
of p65 phosphorylation coincides with inhibition of IkappaBalpha 
polyubiquitination and degradation. Mol Carcinog 44:274-84. 
  81 
50. Hu, J., H. Nakano, H. Sakurai, and N. H. Colburn. 2004. Insufficient p65 
phosphorylation at S536 specifically contributes to the lack of NF-kappaB 
activation and transformation in resistant JB6 cells. Carcinogenesis 
25:1991-2003. 
51. Huang, B., X. D. Yang, A. Lamb, and L. F. Chen. 2010. Posttranslational 
modifications of NF-kappaB: another layer of regulation for NF-kappaB 
signaling pathway. Cell Signal 22:1282-90. 
52. Ikari, Y., B. M. McManus, J. Kenyon, and S. M. Schwartz. 1999. Neonatal 
intima formation in the human coronary artery. Arterioscler Thromb Vasc 
Biol 19:2036-40. 
53. Inbal, B., S. Bialik, I. Sabanay, G. Shani, and A. Kimchi. 2002. DAP kinase 
and DRP-1 mediate membrane blebbing and the formation of autophagic 
vesicles during programmed cell death. J Cell Biol 157:455-68. 
54. Inbal, B., O. Cohen, S. Polak-Charcon, J. Kopolovic, E. Vadai, L. 
Eisenbach, and A. Kimchi. 1997. DAP kinase links the control of apoptosis 
to metastasis. Nature 390:180-4. 
55. Ishibashi, S., M. S. Brown, J. L. Goldstein, R. D. Gerard, R. E. Hammer, 
and J. Herz. 1993. Hypercholesterolemia in low density lipoprotein 
receptor knockout mice and its reversal by adenovirus-mediated gene 
delivery. J Clin Invest 92:883-93. 
56. Iyer, V., K. Pumiglia, and C. M. DiPersio. 2005. Alpha3beta1 integrin 
regulates MMP-9 mRNA stability in immortalized keratinocytes: a novel 
mechanism of integrin-mediated MMP gene expression. J Cell Sci 
118:1185-95. 
57. Jang, Y., A. M. Lincoff, E. F. Plow, and E. J. Topol. 1994. Cell adhesion 
molecules in coronary artery disease. J Am Coll Cardiol 24:1591-601. 
58. Jin, Y., E. K. Blue, S. Dixon, L. Hou, R. B. Wysolmerski, and P. J. 
Gallagher. 2001. Identification of a new form of death-associated protein 
kinase that promotes cell survival. J Biol Chem 276:39667-78. 
59. Jin, Y., E. K. Blue, S. Dixon, Z. Shao, and P. J. Gallagher. 2002. A death-
associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 
ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and 
regulates the cellular levels of DAPK. J Biol Chem 277:46980-6. 
60. Jin, Y., E. K. Blue, and P. J. Gallagher. 2006. Control of death-associated 
protein kinase (DAPK) activity by phosphorylation and proteasomal 
degradation. J Biol Chem 281:39033-40. 
61. Jin, Y., and P. J. Gallagher. 2003. Antisense depletion of death-associated 
protein kinase promotes apoptosis. J Biol Chem 278:51587-93. 
62. Johnson, C., and Z. S. Galis. 2004. Matrix metalloproteinase-2 and -9 
differentially regulate smooth muscle cell migration and cell-mediated 
collagen organization. Arterioscler Thromb Vasc Biol 24:54-60. 
  82 
63. Kishino, M., K. Yukawa, K. Hoshino, A. Kimura, N. Shirasawa, H. Otani, T. 
Tanaka, K. Owada-Makabe, Y. Tsubota, M. Maeda, M. Ichinose, K. 
Takeda, S. Akira, and M. Mune. 2004. Deletion of the kinase domain in 
death-associated protein kinase attenuates tubular cell apoptosis in renal 
ischemia-reperfusion injury. J Am Soc Nephrol 15:1826-34. 
64. Kissil, J. L., E. Feinstein, O. Cohen, P. A. Jones, Y. C. Tsai, M. A. 
Knowles, M. E. Eydmann, and A. Kimchi. 1997. DAP-kinase loss of 
expression in various carcinoma and B-cell lymphoma cell lines: possible 
implications for role as tumor suppressor gene. Oncogene 15:403-7. 
65. Knowles, J. W., and N. Maeda. 2000. Genetic modifiers of atherosclerosis 
in mice. Arterioscler Thromb Vasc Biol 20:2336-45. 
66. Knox, J. B., G. K. Sukhova, A. D. Whittemore, and P. Libby. 1997. 
Evidence for altered balance between matrix metalloproteinases and their 
inhibitors in human aortic diseases. Circulation 95:205-12. 
67. Koyama, N., M. G. Kinsella, T. N. Wight, U. Hedin, and A. W. Clowes. 
1998. Heparan sulfate proteoglycans mediate a potent inhibitory signal for 
migration of vascular smooth muscle cells. Circ Res 83:305-13. 
68. Ku, D. N., D. P. Giddens, C. K. Zarins, and S. Glagov. 1985. Pulsatile flow 
and atherosclerosis in the human carotid bifurcation. Positive correlation 
between plaque location and low oscillating shear stress. Arteriosclerosis 
5:293-302. 
69. Kumar, A., and V. Lindner. 1997. Remodeling with neointima formation in 
the mouse carotid artery after cessation of blood flow. Arterioscler Thromb 
Vasc Biol 17:2238-44. 
70. Kuo, J. C., J. R. Lin, J. M. Staddon, H. Hosoya, and R. H. Chen. 2003. 
Uncoordinated regulation of stress fibers and focal adhesions by DAP 
kinase. J Cell Sci 116:4777-90. 
71. Kuo, J. C., W. J. Wang, C. C. Yao, P. R. Wu, and R. H. Chen. 2006. The 
tumor suppressor DAPK inhibits cell motility by blocking the integrin-
mediated polarity pathway. J Cell Biol 172:619-31. 
72. Lawrence, T., M. Bebien, G. Y. Liu, V. Nizet, and M. Karin. 2005. IKKalpha 
limits macrophage NF-kappaB activation and contributes to the resolution 
of inflammation. Nature 434:1138-43. 
73. Leber, T. M., and F. R. Balkwill. 1997. Zymography: a single-step staining 
method for quantitation of proteolytic activity on substrate gels. Anal 
Biochem 249:24-8. 
74. Lessner, S. M., D. E. Martinson, and Z. S. Galis. 2004. Compensatory 
vascular remodeling during atherosclerotic lesion growth depends on 
matrix metalloproteinase-9 activity. Arterioscler Thromb Vasc Biol 
24:2123-9. 
75. Li, H., M. W. Freeman, and P. Libby. 1995. Regulation of smooth muscle 
cell scavenger receptor expression in vivo by atherogenic diets and in vitro 
by cytokines. J Clin Invest 95:122-33. 
  83 
76. Li, H., J. Liang, D. H. Castrillon, R. A. DePinho, E. N. Olson, and Z. P. Liu. 
2007. FoxO4 regulates tumor necrosis factor alpha-directed smooth 
muscle cell migration by activating matrix metalloproteinase 9 gene 
transcription. Mol Cell Biol 27:2676-86. 
77. Li, X., V. Van Putten, F. Zarinetchi, M. E. Nicks, S. Thaler, L. E. Heasley, 
and R. A. Nemenoff. 1997. Suppression of smooth-muscle alpha-actin 
expression by platelet-derived growth factor in vascular smooth-muscle 
cells involves Ras and cytosolic phospholipase A2. Biochem J 327 ( Pt 
3):709-16. 
78. Lin, Y., T. R. Hupp, and C. Stevens. 2010. Death-associated protein 
kinase (DAPK) and signal transduction: additional roles beyond cell death. 
FEBS J 277:48-57. 
79. Lindner, V., J. Fingerle, and M. A. Reidy. 1993. Mouse model of arterial 
injury. Circ Res 73:792-6. 
80. Lusis, A. J. 2000. Atherosclerosis. Nature 407:233-41. 
81. Martinet, W., D. M. Schrijvers, G. R. De Meyer, J. Thielemans, M. W. 
Knaapen, A. G. Herman, and M. M. Kockx. 2002. Gene expression 
profiling of apoptosis-related genes in human atherosclerosis: upregulation 
of death-associated protein kinase. Arterioscler Thromb Vasc Biol 
22:2023-9. 
82. Mason, D. P., R. D. Kenagy, D. Hasenstab, D. F. Bowen-Pope, R. A. 
Seifert, S. Coats, S. M. Hawkins, and A. W. Clowes. 1999. Matrix 
metalloproteinase-9 overexpression enhances vascular smooth muscle 
cell migration and alters remodeling in the injured rat carotid artery. Circ 
Res 85:1179-85. 
83. Moon, S. K., B. Y. Cha, and C. H. Kim. 2004. ERK1/2 mediates TNF-
alpha-induced matrix metalloproteinase-9 expression in human vascular 
smooth muscle cells via the regulation of NF-kappaB and AP-1: 
Involvement of the ras dependent pathway. J Cell Physiol 198:417-27. 
84. Moses, H. L., E. Y. Yang, and J. A. Pietenpol. 1990. TGF-beta stimulation 
and inhibition of cell proliferation: new mechanistic insights. Cell 63:245-7. 
85. Natoli, G., S. Saccani, D. Bosisio, and I. Marazzi. 2005. Interactions of NF-
kappaB with chromatin: the art of being at the right place at the right time. 
Nat Immunol 6:439-45. 
86. Newby, A. C. 2005. Dual role of matrix metalloproteinases (matrixins) in 
intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85:1-31. 
87. Newby, A. C. 2006. Matrix metalloproteinases regulate migration, 
proliferation, and death of vascular smooth muscle cells by degrading 
matrix and non-matrix substrates. Cardiovasc Res 69:614-24. 
88. Ni, W., K. Egashira, S. Kitamoto, C. Kataoka, M. Koyanagi, S. Inoue, K. 
Imaizumi, C. Akiyama, K. I. Nishida, and A. Takeshita. 2001. New anti-
monocyte chemoattractant protein-1 gene therapy attenuates 
atherosclerosis in apolipoprotein E-knockout mice. Circulation 103:2096-
101. 
  84 
89. O'Brien, K. D., M. D. Allen, T. O. McDonald, A. Chait, J. M. Harlan, D. 
Fishbein, J. McCarty, M. Ferguson, K. Hudkins, C. D. Benjamin, and et al. 
1993. Vascular cell adhesion molecule-1 is expressed in human coronary 
atherosclerotic plaques. Implications for the mode of progression of 
advanced coronary atherosclerosis. J Clin Invest 92:945-51. 
90. Owens, G. K., M. S. Kumar, and B. R. Wamhoff. 2004. Molecular 
regulation of vascular smooth muscle cell differentiation in development 
and disease. Physiol Rev 84:767-801. 
91. Paigen, B., A. Morrow, C. Brandon, D. Mitchell, and P. Holmes. 1985. 
Variation in susceptibility to atherosclerosis among inbred strains of mice. 
Atherosclerosis 57:65-73. 
92. Pan, J. H., G. K. Sukhova, J. T. Yang, B. Wang, T. Xie, H. Fu, Y. Zhang, 
A. R. Satoskar, J. R. David, C. N. Metz, R. Bucala, K. Fang, D. I. Simon, 
H. A. Chapman, P. Libby, and G. P. Shi. 2004. Macrophage migration 
inhibitory factor deficiency impairs atherosclerosis in low-density 
lipoprotein receptor-deficient mice. Circulation 109:3149-53. 
93. Pidkovka, N. A., O. A. Cherepanova, T. Yoshida, M. R. Alexander, R. A. 
Deaton, J. A. Thomas, N. Leitinger, and G. K. Owens. 2007. Oxidized 
phospholipids induce phenotypic switching of vascular smooth muscle 
cells in vivo and in vitro. Circ Res 101:792-801. 
94. Piedrahita, J. A., S. H. Zhang, J. R. Hagaman, P. M. Oliver, and N. 
Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene 
inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci 
U S A 89:4471-5. 
95. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. 
Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe 
hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient 
mice created by homologous recombination in ES cells. Cell 71:343-53. 
96. Raines, E. W., and N. Ferri. 2005. Thematic review series: The immune 
system and atherogenesis. Cytokines affecting endothelial and smooth 
muscle cells in vascular disease. J Lipid Res 46:1081-92. 
97. Reusch, P., H. Wagdy, R. Reusch, E. Wilson, and H. E. Ives. 1996. 
Mechanical strain increases smooth muscle and decreases nonmuscle 
myosin expression in rat vascular smooth muscle cells. Circ Res 79:1046-
53. 
98. Rong, J. X., M. Shapiro, E. Trogan, and E. A. Fisher. 2003. 
Transdifferentiation of mouse aortic smooth muscle cells to a 
macrophage-like state after cholesterol loading. Proc Natl Acad Sci U S A 
100:13531-6. 
99. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 
1990s. Nature 362:801-9. 
100. Roy, J., P. K. Tran, P. Religa, M. Kazi, B. Henderson, K. Lundmark, and 
U. Hedin. 2002. Fibronectin promotes cell cycle entry in smooth muscle 
cells in primary culture. Exp Cell Res 273:169-77. 
  85 
101. Ruan, X. Z., J. F. Moorhead, J. L. Tao, K. L. Ma, D. C. Wheeler, S. H. 
Powis, and Z. Varghese. 2006. Mechanisms of dysregulation of low-
density lipoprotein receptor expression in vascular smooth muscle cells by 
inflammatory cytokines. Arterioscler Thromb Vasc Biol 26:1150-5. 
102. Sakurai, H., H. Chiba, H. Miyoshi, T. Sugita, and W. Toriumi. 1999. 
IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in 
the transactivation domain. J Biol Chem 274:30353-6. 
103. Sakurai, H., S. Suzuki, N. Kawasaki, H. Nakano, T. Okazaki, A. Chino, T. 
Doi, and I. Saiki. 2003. Tumor necrosis factor-alpha-induced IKK 
phosphorylation of NF-kappaB p65 on serine 536 is mediated through the 
TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278:36916-23. 
104. Sasaki, C. Y., T. J. Barberi, P. Ghosh, and D. L. Longo. 2005. 
Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-
independent NF-{kappa}B pathway. J Biol Chem 280:34538-47. 
105. Sata, M., Y. Maejima, F. Adachi, K. Fukino, A. Saiura, S. Sugiura, T. 
Aoyagi, Y. Imai, H. Kurihara, K. Kimura, M. Omata, M. Makuuchi, Y. 
Hirata, and R. Nagai. 2000. A mouse model of vascular injury that induces 
rapid onset of medial cell apoptosis followed by reproducible neointimal 
hyperplasia. J Mol Cell Cardiol 32:2097-104. 
106. Schumacher, A. M., J. P. Schavocky, A. V. Velentza, S. Mirzoeva, and D. 
M. Watterson. 2004. A calmodulin-regulated protein kinase linked to 
neuron survival is a substrate for the calmodulin-regulated death-
associated protein kinase. Biochemistry 43:8116-24. 
107. Schumacher, A. M., A. V. Velentza, D. M. Watterson, and J. Dresios. 
2006. Death-associated protein kinase phosphorylates mammalian 
ribosomal protein S6 and reduces protein synthesis. Biochemistry 
45:13614-21. 
108. Shani, G., L. Marash, D. Gozuacik, S. Bialik, L. Teitelbaum, G. Shohat, 
and A. Kimchi. 2004. Death-associated protein kinase phosphorylates ZIP 
kinase, forming a unique kinase hierarchy to activate its cell death 
functions. Mol Cell Biol 24:8611-26. 
109. Shohat, G., T. Spivak-Kroizman, O. Cohen, S. Bialik, G. Shani, H. Berrisi, 
M. Eisenstein, and A. Kimchi. 2001. The pro-apoptotic function of death-
associated protein kinase is controlled by a unique inhibitory 
autophosphorylation-based mechanism. J Biol Chem 276:47460-7. 
110. Stary, H. C. 2000. Natural history and histological classification of 
atherosclerotic lesions: an update. Arterioscler Thromb Vasc Biol 20:1177-
8. 
111. Stary, H. C., D. H. Blankenhorn, A. B. Chandler, S. Glagov, W. Insull, Jr., 
M. Richardson, M. E. Rosenfeld, S. A. Schaffer, C. J. Schwartz, W. D. 
Wagner, and et al. 1992. A definition of the intima of human arteries and of 
its atherosclerosis-prone regions. A report from the Committee on 
Vascular Lesions of the Council on Arteriosclerosis, American Heart 
Association. Arterioscler Thromb 12:120-34. 
  86 
112. Stary, H. C., A. B. Chandler, S. Glagov, J. R. Guyton, W. Insull, Jr., M. E. 
Rosenfeld, S. A. Schaffer, C. J. Schwartz, W. D. Wagner, and R. W. 
Wissler. 1994. A definition of initial, fatty streak, and intermediate lesions 
of atherosclerosis. A report from the Committee on Vascular Lesions of 
the Council on Arteriosclerosis, American Heart Association. Arterioscler 
Thromb 14:840-56. 
113. Su, B., S. Mitra, H. Gregg, S. Flavahan, M. A. Chotani, K. R. Clark, P. J. 
Goldschmidt-Clermont, and N. A. Flavahan. 2001. Redox regulation of 
vascular smooth muscle cell differentiation. Circ Res 89:39-46. 
114. Thompson, J. S. 1969. Atheromata in an inbred strain of mice. J 
Atheroscler Res 10:113-22. 
115. Thyberg, J., and A. Hultgardh-Nilsson. 1994. Fibronectin and the 
basement membrane components laminin and collagen type IV influence 
the phenotypic properties of subcultured rat aortic smooth muscle cells 
differently. Cell Tissue Res 276:263-71. 
116. Tian, J. H., S. Das, and Z. H. Sheng. 2003. Ca2+-dependent 
phosphorylation of syntaxin-1A by the death-associated protein (DAP) 
kinase regulates its interaction with Munc18. J Biol Chem 278:26265-74. 
117. Truett, G. E., P. Heeger, R. L. Mynatt, A. A. Truett, J. A. Walker, and M. L. 
Warman. 2000. Preparation of PCR-quality mouse genomic DNA with hot 
sodium hydroxide and tris (HotSHOT). Biotechniques 29:52, 54. 
118. Tu, W., X. Xu, L. Peng, X. Zhong, W. Zhang, M. M. Soundarapandian, C. 
Balel, M. Wang, N. Jia, F. Lew, S. L. Chan, Y. Chen, and Y. Lu. 2010. 
DAPK1 interaction with NMDA receptor NR2B subunits mediates brain 
damage in stroke. Cell 140:222-34. 
119. Van den Steen, P. E., P. Proost, A. Wuyts, J. Van Damme, and G. 
Opdenakker. 2000. Neutrophil gelatinase B potentiates interleukin-8 
tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, 
and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 96:2673-
81. 
120. Velentza, A. V., A. M. Schumacher, C. Weiss, M. Egli, and D. M. 
Watterson. 2001. A protein kinase associated with apoptosis and tumor 
suppression: structure, activity, and discovery of peptide substrates. J Biol 
Chem 276:38956-65. 
121. Wang, W. J., J. C. Kuo, C. C. Yao, and R. H. Chen. 2002. DAP-kinase 
induces apoptosis by suppressing integrin activity and disrupting matrix 
survival signals. J Cell Biol 159:169-79. 
122. Weninger, W. J., G. B. Muller, C. Reiter, S. Meng, and S. U. Rabl. 1999. 
Intimal hyperplasia of the infant parasellar carotid artery: a potential 
developmental factor in atherosclerosis and SIDS. Circ Res 85:970-5. 
123. Widau, R. C., Y. Jin, S. A. Dixon, B. E. Wadzinski, and P. J. Gallagher. 
2010. Protein phosphatase 2A (PP2A) holoenzymes regulate death-
associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol 
Chem 285:13827-38. 
  87 
124. Woodside, K. J., A. Hernandez, F. W. Smith, X. Y. Xue, M. Hu, J. A. 
Daller, and G. C. Hunter. 2003. Differential gene expression in primary 
and recurrent carotid stenosis. Biochem Biophys Res Commun 302:509-
14. 
125. Xin, H. B., K. Y. Deng, M. Rishniw, G. Ji, and M. I. Kotlikoff. 2002. Smooth 
muscle expression of Cre recombinase and eGFP in transgenic mice. 
Physiol Genomics 10:211-5. 
126. Xu, Q. 2004. Mouse models of arteriosclerosis: from arterial injuries to 
vascular grafts. Am J Pathol 165:1-10. 
127. Yang, J., G. H. Fan, B. E. Wadzinski, H. Sakurai, and A. Richmond. 2001. 
Protein phosphatase 2A interacts with and directly dephosphorylates 
RelA. J Biol Chem 276:47828-33. 
128. Zalckvar, E., H. Berissi, L. Mizrachy, Y. Idelchuk, I. Koren, M. Eisenstein, 
H. Sabanay, R. Pinkas-Kramarski, and A. Kimchi. 2009. DAP-kinase-
mediated phosphorylation on the BH3 domain of beclin 1 promotes 
dissociation of beclin 1 from Bcl-XL and induction of autophagy. EMBO 
Rep 10:285-92. 
129. Zhang, L., K. P. Nephew, and P. J. Gallagher. 2007. Regulation of death-
associated protein kinase. Stabilization by HSP90 heterocomplexes. J Biol 
Chem 282:11795-804. 
130. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. 
Spontaneous hypercholesterolemia and arterial lesions in mice lacking 
apolipoprotein E. Science 258:468-71. 
131. Zhou, J., E. K. Blue, G. Hu, and B. P. Herring. 2008. Thymine DNA 
glycosylase represses myocardin-induced smooth muscle cell 
differentiation by competing with serum response factor for myocardin 
binding. J Biol Chem 283:35383-92. 
 
 
 
 
 
 
 
 
Curriculum Vitae  
Emily Keller Blue 
 
Education 
8/04-12/10  PhD, Cellular and Integrative Physiology 
   Minor: Diabetes and Obesity 
Indiana University, Indianapolis, IN 
Advisor: Dr. Patricia J. Gallagher 
8/91-8/95  BS Biochemistry with high distinction 
   Indiana University, Bloomington, IN 
 
Research Experience 
7/99-8/04  Research Analyst  
   Indiana University School of Medicine, Indianapolis, IN 
   Cellular and Integrative Physiology 
   Lab: Dr. Patricia J. Gallagher 
2/98-7/99  Research Technician 
   Indiana University School of Medicine, Indianapolis, IN 
4/96-10/97  Biochemist 
   National Starch and Chemical Company, Bridgewater, NJ 
   Natural Polymer Research 
5/94-8/95  Undergraduate Researcher 
   Indiana University, Bloomington, IN 
   Department of Chemistry 
 
Awards And Honors 
IUPUI Dissertation Scholarship Award: 2010 
American Heart Association Predoctoral Fellowship: 2008-2010 
GK-12 Fellowship: 2008-2009  
NSF grant to IU School of Medicine (declined due to overlapping funding) 
Sigma Xi Research Competition, 3rd place: June 2008 
Diabetes and Obesity Fellowship: 2006-2008 
 T32 Training Grant to Indiana University 
Moenkhaus Graduate Physiology Fellowship: 2005-2006 
 Cellular and Integrative Physiology, Indiana University School of Medicine 
University Fellowship: 2004-2005 
 Indiana University, Graduate School 
Phi Beta Kappa, Indiana University 
Golden Key National Honor Society, Indiana University 
Honors in Chemistry, Indiana University 
Publications 
E.K. Blue , F. Li, D.A. Ingram, Jr., B.P. Herring, and P.J. Gallagher. DAPK blocks 
MMP9 expression in vascular smooth muscle cells via indirect regulation 
of NF-κB p65 phosphorylation. (In preparation) 
K.M. Habegger, L. Tackett, L.N. Bell, M.Y. Awad, P.J. Gallagher, E.K. Blue, M. 
Sturek, M. A. Alloosh, H. O. Steinberg, R.V. Considine, and J.S. 
Elmendorf. Fatty Acid-Induced Plasma Membrane Cholesterol Accrual and 
Insulin Resistance. (In revision) 
J. Zhou, E.K. Blue, G. Hu, & B.P. Herring. 2008. Thymine DNA glycosylase 
represses myocardin-induced smooth muscle cell differentiation by 
competing with SRF for myocardin binding. J. Biol Chem. 283:35383-92. 
Y. Jin, E.K. Blue, and P.J. Gallagher. 2006. Control of death associated protein 
kinase (DAPK) activity by phosphorylation and proteasomal degradation. J 
Biol Chem. 281:39033-40. 
E.K. Blue*, Z.M. Goeckeler*, Y. Jin, L. Hou, S.A. Dixon, B.P. Herring, R.B. 
Wysolmerski, and P.J. Gallagher. 2002. 220- and 130-kDa MLCKs have 
distinct tissue distributions and intracellular localization patterns. Am J 
Physiol Cell Physiol. 282:C451-60. 
Y. Jin*, E.K. Blue*, S. Dixon, Z. Shao, and P.J. Gallagher. 2002. A death-
associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 
ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and 
regulates the cellular levels of DAPK. J Biol Chem. 277:46980-6. 
Y. Jin*, E.K. Blue*, S. Dixon, L. Hou, R.B. Wysolmerski, and P.J. Gallagher. 
2001. Identification of a new form of death-associated protein kinase that 
promotes cell survival. J Biol Chem. 276:39667-78. 
P.J. Gallagher, Y. Jin, G. Killough, E.K. Blue, and V. Lindner. 2000. Alterations in 
expression of myosin and myosin light chain kinases in response to 
vascular injury. Am J Physiol Cell Physiol. 279:C1078-87. 
W.L. Nowatzke, E. Keller, G. Koch, and J.P. Richardson. 1997. Transcription 
term-ination factor Rho is essential for Micrococcus luteus. J Bacteriol. 
179:5238-40. 
*Both authors made equal contributions to the work. 
 
Abstracts 
North American Vascular Biology Organization/Experimental Biology 2007: Blue, 
E.K. and Gallagher, P.J. "Role of DAP kinase in atherosclerosis and 
inflammation" (April 2007, Oral Presentation) 
NAVBO Signaling in the Cardiovascular System Workshop:  "DAPK: A Novel 
Mediator and Target of TGF-beta Signaling in Vascular Smooth Muscle" 
(September 2008, poster) 
 
Meetings/Courses Attended 
American Society for Cell Biology, December 1999 
Experimental Biology, April 2001 
Vasculata Vascular Biology Course (NAVBO), July 2004 
American Diabetes Association, June 2005 
IU Continuing Medical Education Grant Writing Workshop, October 2005 
Preparing Future Faculty Program, December 2005-May 2008 
Experimental Biology, April 2007 
NAVBO Signaling in the Cardiovascular System Workshop, September 2008 
 
Service 
Tutor for Chemistry, Biology, and Math: IU School of Medicine/Crispus Attucks 
Medical Magnet Program, 2009-2010 
Cellular and Integrative Physiology Graduate Student Representative to Indiana 
University School of Medicine (IUSM), 2006-2007 
• Organizer and judging panelist: Student Travel Grant Competition: 2006-
2007 
• Physiology Department Seminar Committee, Student Representative: 
2006-2007 
IUSM Graduate Student Representative to campus-wide IUPUI Graduate Student 
Organization: 2006-2007 
• Judging panelist: IUPUI Campus-wide Educational Enhancement Grant 
Competition: 2006-2007 
 
Professional Associations 
North American Vascular Biology Organization, 2006-2009 
American Academy for the Advancement of Science, 2007-2009 
American Physiology Association, 2008-2009 
 
Presentations 
Departmental Research in Progress, January 2006, "A potential role for DAPK in 
vascular smooth muscle differentiation" (Oral Presentation) 
Sigma Xi research competition, June 2006, "A potential role for DAPK in 
regulation of vascular smooth muscle differentiation" (Oral Presentation) 
Indiana Center for Vascular Biology, September 2006, "Regulation of death-
associated protein kinase (DAPK) expression in smooth muscle cells" 
(Poster) 
Departmental Research in Progress, January 2007, "Potential roles for DAPK in 
vascular smooth muscle" (Oral Presentation) 
North American Vascular Biology Organization/Experimental Biology 2007, April 
2007, "Role of DAP kinase in atherosclerosis and inflammation" (Oral 
Presentation) 
Departmental retreat, August 2007, "Role of DAPK in atherosclerosis and 
inflammation" (Oral Presentation) 
Sigma Xi research competition, May 2008, "DAPK: A novel mediator and target 
of TGF-beta signaling in vascular smooth muscle" (Oral Presentation) 
Departmental Research in Progress, August 2008, "DAPK, TGF-beta, and ECM: 
New roles for a kinase in vascular smooth muscle"  (Oral Presentation) 
Departmental Retreat, August 2008, "DAPK: A Novel Mediator and Target of 
TGF-beta Signaling in Vascular Smooth Muscle" (Poster) 
NAVBO Signaling in the Cardiovascular System Workshop, September 2008, 
"DAPK: A Novel Mediator and Target of TGF-beta Signaling in Vascular 
Smooth Muscle" (Poster)  
Indiana University School of Medicine Biannual Dean’s Grand Rounds and 
Scientific Sessions, September 2008, "DAPK: A Novel Mediator and 
Target of TGF-beta Signaling in Vascular Smooth Muscle" (Poster)  
Departmental Research in Progress, August 2009, "Regulation of Vascular 
Smooth Muscle Migration and Adhesion by DAPK" (Oral Presentation) 
